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Background: Loss of the trachea and proximal airway from congenital disorders, acute injury or 
chronic disease is a life-threatening complication. The lack of suitable native replacements has 
led to attempts to bioengineer tracheas. Recent clinical cases of bioengineered tracheal 
transplants have been hampered by an inability to maintain growing cell populations. The 
majority of cases have ended in significant acute and chronic complications, morbidity and 
death.  A growing body of literature has found that a ligand-receptor interaction between the 
secreted protein thrombospodin-1 (TSP1) and its high affinity receptor CD47, which is 
upregulated in tissue injury, constitutively restricts multiple key transcription factors that 
modulate self-renewal and pluripotency.   
Hypothesis: TSP1-CD47 signaling is maladaptively induced in injured airways and 
bioengineered tracheas to inhibit cellular dedifferentiation, proliferation and restoration of 
engineered tracheal transplants.   
Methods: This dissertation first describes a murine orthotopic tracheal transplant model and 
second describes methods to characterize the effects of TSP1-CD47 signaling on airway 
epithelial cells.  In vitro, airway epithelial cell wound healing and tissue angiogenic capacity was 
assessed using a variety of techniques. In vivo, naphthalene injury and orthotopic transplantation 
of decellularized tracheal grafts was performed in wild-type mice or in mice that lacked TSP1-
CD47 signaling, and epithelial restoration and transplant healing were assessed.   
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Johannes Craig Kutten, Ph. D. 
University of Pittsburgh, 2016
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Results: Decellularized tracheal grafts support re-epithelization within seven days and epithelial 
differentiation within eight weeks after transplantation. Disruption of TSP1-CD47 signaling 
restores self-renewal gene expression in tracheal epithelial cells exposed to hypoxic stress and 
stimulates more rapid wound healing in an in vitro model of airway injury. TSP1 inhibits 
proliferation of airway epithelial cells while antibody blockade of CD47 restores cell 
proliferation. Further, TSP1 is upregulated following airway epithelial cell seeding onto 
decellularized and synthetic tracheal scaffolds.  TSP1-CD47 signaling is induced in the airways 
of WT mice after injury. CD47 null mice displayed enhanced tracheal healing of both chemically 
injured airways and following orthotopic transplantation of decellularized tracheal grafts.  
Conclusion: TSP1-CD47 signaling is maladaptively upregulated in stressed tracheal epithelial 
cells, in injured airways, in cells seeded on decellularized and synthetic tracheal grafts, and in 
engineered tracheal transplants to limit self-renewal gene expression and inhibit cell 
proliferation, airway healing and cellular incorporation of bioengineered tracheal transplants. 
 
 vi 
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1.0  INTRODUCTION 
Tracheal injuries and defects are rare, but are in many instances fatal.  Despite the development 
of reparative protocols such as slide tracheoplasty, there remains a population of patients for 
whom there are no therapies available. These include pediatric patients with congenital defects 
and adults with tracheal tumors.  In these patients, tracheal transplantation or replacement with a 
bioengineered graft would be a life-saving therapy.  In spite of this, attempts to prepare 
bioengineered tracheal transplants have been unsuccessful, and new approaches are needed to 
generate grafts which support functional cell populations.   
Thrombpsondin-1 (TSP1)-CD47 signaling represents a particular cell matrix interaction 
which may limit the survival of cells in tissues after transplantation.  TSP1 is deposited in the 
extracellular matrix by cells under stress.  It ligates with its high affinity cell receptor, CD47.  
TSP1 activation of CD47 redundantly inhibits tissue survival through effects on angiogenesis 
and self-renewal. Thus, TSP1 which is (1) retained in the extracellular matrix, or (2) is secreted 
by cells migrating into and repopulating decellularized or synthetic tracheal scaffold, can limit 
the survival of grafts and whole transplants.  
I hypothesize that TSP1, via cell-surface receptor CD47, inhibits cellular survival 
and engraftment within decellularized tracheal grafts.  The aims of this dissertation project 
were as follows: (1) to establish a murine model of tracheal transplantation for studies examining 
the role of specific cell-matrix interactions in airway repair and regeneration.  (2) to examine the 
 2 
effects of TSP1-CD47 signaling on airway epithelial cells in vitro, and (3) to demonstrate that 
interference with the TSP1-CD47 signaling axis (via the use of mutant mouse models) can 
improve outcomes in orthotopic decellularized tracheal transplantation.  
This project describes a novel mechanism by which cell-matrix interactions limit cell 
survival and reconstitution of bioengineered decellularized and putatively synthetic tracheal 
grafts. The knowledge generated by this project will support the use of CD47-blocking 
therapeutics to improve outcomes in tissue engineered transplants. 
1.1 DESCRIPTION OF CONTENTS 
Chapter 2 describes the anatomy, development, physiology, and pathology on the trachea and 
provides some background on airway transplantation.  It also describes the publically available 
data on the first human trials of bioengineered tracheal transplants, as these preliminary cases 
and the results therein have already had an impact on the field of tracheal tissue bioengineering 
specifically and tissue engineering in general.  Chapter 3 describes the murine orthotopic tracheal 
transplant model. It borrows heavily from my publication in Tissue Engineering Part A (2015) 
[1].  Chapter 4 provides background on thrombospondin-1 (TSP1) and CD47 signaling, and 
describes our efforts to generate a floxed CD47 mouse for future work examining cell-specific 
CD47 knockouts. Chapter 5 explores a technique which was developed here in the Isenberg lab 
to determine whether or not the CD47 null genotype leads to increased numbers of basal cells 
within the airway epithelium. Finally, Chapter 6 describes our experience transplanting 
decellularized tracheal grafts into wild type (CD47 positive) and CD47 null mice.   
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2.0  BACKGROUND 
 
The trachea is a vital organ which functions as the conduit between the external environment and 
the respiratory epithelium. There is a subset of patients with long-segment tracheal defects for 
whom current surgical protocols are insufficient. For these patients, tracheal transplantation 
represents a potentially lifesaving intervention.   
Tracheal anatomy, development, physiology, and pathology are reviewed in this 
introduction. Present techniques of tracheal repair and associated pitfalls are examined.    Finally, 
a discussion of matricellular signaling within decellularized grafts forms the rationale for my 
research plan.   
2.1 THE TRACHEA 
2.1.1 Anatomy 
The trachea is a vascularized tube extending from the larynx to the level of the fourth thoracic 
vertebra. In adult humans it is about 10-13 centimeters in length and 1.5-2 centimeters in 
diameter. It is surrounded by the adventitia, a layer of loose connective tissue which anchors it to 
surrounding structures [2].  
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The lumen is lined by a pseudostratified columnar epithelium comprised of three major 
cell types: (1) ciliated cells which provide mucociliary clearance; (2) club secretory cells, which 
fulfill a variety of roles related to the maintenance of the immune barrier; and (3) basal cells, 
which act as the progenitor cells of the proximal airway epithelium. The epithelium and the 
highly vascularized lamina propria together comprise the tracheal mucosa.  
Patency of the trachea is maintained by up to 20 equally-spaced hyaline cartilaginous 
rings. These rings are “incomplete” (C-shaped) with their opening on the dorsal side. This 
opening is covered by a layer of smooth muscle (m. trachealis) which narrows the trachea under 
autonomic stimuli and separates the tracheal lumen from the esophagus.   
The cervical trachea is perfused by tracheoesophageal branches of the inferior thyroidal 
artery, whereas the inferior trachea and carina are supplied by the bronchial arteries [3, 4].  
Venous drainage is provided by the inferior thyroid venous plexus [4]. The adult tracheal 
microvasculature within the lamina propria provides segmental perfusion to the epithelium. 
Circumferentially-oriented arterioles and venules are found in the intercartilaginous zones, 
whereas longitudinal capillaries cross cartilaginous rings [5, 6]. 
2.1.2 Development 
The trachea is comprised of tissue of both endodermal and mesodermal origin. Interactions 
between these two germ layers are responsible for the formation of the primitive gut tube and the 
development of the airways [7, 8].  
The tracheal epithelium is derived from the foregut endoderm which initially expresses 
Foxa1, Foxa2, Gata4 and Gata6 [8]. Around developmental day E9.0 (day 22 in humans), 
epithelial cells of the ventral foregut endoderm are driven toward a respiratory lineage by the 
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expression of Nkx2.1 (also known as Ttf1 or T/EBP) [9].  Nkx2.1 (expressed ventrally) and Sox2 
(expressed dorsally) are thought to counter-regulate each other [10].  Cells of the dorsal foregut 
endoderm take on characteristics of the esophageal epithelium through expression of high levels 
of Sox2 [8, 9, 11], whereas moderate-to-low Sox2 expression defines the conducting airway 
phenotype.  
Proper Sox2 signaling is critical for maintenance of the conducting airway epithelium in 
adults. The presence of Sox2 is thought to specify the airway epithelium toward a proximal 
(versus distal) phenotype [12], and precise levels of Sox2 are necessary for maintenance of the 
respiratory epithelium’s club, ciliated, and basal cells [13]. Sox2 deletion (after birth) leads to an 
excess number of mucus-producing cells, and a lower proportion of p63-positive basal cells [10].  
Total loss of Sox2 expression leads to a cuboidal and squamous cell phenotype [14].  Further, 
Sox2 is necessary to maintain the self-renewal capacity of airway basal cells in vitro, and is 
required for regeneration of the tracheal epithelium in models of airway injury [15].   
Tracheal cartilage is of splanchnic mesodermal origin.  Transcription factors Tbx4, Tbx5 
and Sox9 are critical for the patterning and development of the cartilaginous rings.  Specification 
of the splanchnic mesoderm immediately adjacent to the foregut endoderm begins with 
expression of transcription factors Tbx4 and Tbx5.  By E11.5 Tbx4/5 are expressed throughout 
the mesenchyme surrounding the primitive tracheal tube [16].  By E13.5, Sox9 expression 
appears in a ring-like pattern corresponding to sites of future cartilaginous rings.  Cells in these 
regions express collagen 2a, and exert negative feedback to suppress expression of Tbx4/5 [16, 
17]. Thus, by E15.5, Tbx4/5 are only expressed in the spaces between the Sox9-expressing 
cartilaginous rings [17]. Loss of Sox9 expression in mesenchymal cells is associated with a 
failure to develop tracheal rings and death due to tracheal collapse [17].   
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Studies of mouse tracheal development have indicated that the embryonic trachea is 
supplied by a primitive, highly anastomotic vascular plexus, structurally similar to that of the 
yolk sac [5]. This plexus is pruned to its segmental, hierarchal adult form between days E16.5 
and P7. During this period, blood vessels crossing the cartilaginous rings regress and are 
replaced by longitudinally-oriented capillaries. Vessels in intercartilaginous sites are replaced 
with circumferential arterioles and venules. Variances in VEGF signaling, oxygen tension, and 
bio-mechanical load are thought to be responsible for this effect [5, 6]. 
2.1.3 Physiology 
In the context of regenerative medicine, the physiology of the native tissue defines the design 
requirements of a tissue engineered graft.   
2.1.3.1 Epithelial physiology 
The tracheal epithelium of the mouse is histologically similar to the human trachea and 
main stem bronchi [2]. This pseudostratified epithelium consists of ciliated, club, and basal cells. 
It is characterized by (1) the presence of intracellular junctions, (2) secretion of antimicrobial 
products, (3) a mucociliary elevator. It is therefore a component of the innate immune barrier. 
This barrier function is particularly important because the trachea and thus engineered tracheal 
transplants sits at the interface between the non-sterile external environment and underlying 
sterile tissues. This localization distinguishes the trachea from prostheses which have been 
implanted in sterile mesenchymal tissues (such as vascular grafts and heart valves) [18, 19]. 
Rapid reconstitution of the tracheal epithelium is thought to limit scar tissue formation following 
injury and/or transplantation [20]. Published reports have made note of the presence of 
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granulation tissue along the luminal surface of tracheal grafts, which creates iatrogenic stenosis 
[18]. Re-epithelializaiton, when it does occur, halts the fibrotic process. Thus, a functioning 
epithelium is critical for any engineered tracheal transplant.  
Basal cells are widely considered to be the progenitor cells of the proximal airway 
epithelium, and the trachea [7, 21-25]. These cells are relatively undifferentiated at baseline and 
are characterized by expression of the transcription factor p63 and the structural protein keratin-
5.  A second intermediate filament protein, keratin-14, is upregulated after injury as basal cells 
proliferate and differentiate. In naphthalene [22, 26-28], sulfur dioxide [27, 29], polidocanol 
[27], and chlorine [30] injury models, basal cells reconstitute the various cell types of the airway 
epithelium. The exact intracellular processes governing basal cell differentiation are unknown, 
though it has been proposed that a Notch signaling event converts these basal cells into a p63-
negative, keratin-8-positive early progenitor, from which other cells differentiate [29].   
Ciliated cells express the transcription factor FoxJ1 and are identified histologically by 
expression of acetylated tubulin. They propel mucus toward the larynx where it can be expelled.  
The total volume of mucus produced in a given day averages 10 ml, but this amount can increase 
significantly in patients who are ill as the body attempts to remove cellular debris and microbial 
components [3]. Failure to clear airway secretions can lead to fatal airway obstruction. Thus, 
ciliated cells are another key component of any engineered tracheal graft, and an analysis of 
ciliary beat has been included in several models of tracheal repair [1]. 
Club cells (formerly known as Clara cells) are a tall, dome-shaped secretory cell 
population present in both the trachea and the bronchioles [31]. They produce a variety of 
molecules involved in creating the innate immune barrier of the airway epithelium, including 
proteases, antimicrobial peptides, and cytokines [31]. They have also been implicated in the 
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production of surfactant [32]. The presence of cytochrome P450 enzymes in these cells gives 
them the capacity to detoxify inhaled substances. A particular subpopulation of club cells within 
the bronchioles is thought to have a limited capacity to differentiate into other cell types, and 
thus can act as a progenitor cell population [30, 31, 33]. Despite their heterogeneity, club cells 
are uniformly identified through their production of the immunoregulatory peptide club cell 
secretory protein (CCSP, also known as CC10, secretogobulin 1a1 [SCGB1A1], and 
uterogobulin) [30].    
2.1.3.2 Cartilaginous rings 
 The C-shaped cartilaginous rings consist of hyaline cartilage and primarily act to 
maintain the patency of the trachea. Signals from the cartilaginous rings may regulate 
development of the tracheal epithelium. Reports indicate that the tracheal epithelium in Sox9 
mutants adopts a “distal” phenotype with greater numbers of club cells and reduced numbers of 
basal cells [17].  This change in epithelial phenotype is thought to be secondary to either (1) a 
loss of Fgf10 expression in the Sox9 mutants or (2) a loss in mechanical support [17].  
Cartilaginous rings are theoretically necessary to prevent collapse of any engineered tracheal 
transplant; however, cartilage has not been yet shown to regenerate in orthotopic [1] or 
heterotopic [34] models of tracheal transplantation.    
2.1.3.3 Connective tissue and vascular function 
Branches of the inferior thyroidal artery and bronchiolar arteries provide segmental 
perfusion to the trachea.  In both mice and humans, microvessels anastomose along the lateral 
aspect of the trachea and penetrate the spaces in between each cartilaginous ring [4]. These 
vessels penetrate to the lamina propria, a layer of loose connective tissue which underlies the 
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epithelium [2]. Arterioles and venules run circumferentially in the mucosa between each 
cartilaginous ring, whereas capillaries cross each ring in a longitudinal fashion [5].  Superficial 
regions of the lamina propria are populated by lymphocytes which act as a component of the 
mucosal-associated lymphoid tissue. Connective tissue fibers condense and become elastic fibers 
in deeper layers of the lamina propria. Thus, the lamina propria provides nutritional, mechanical, 
and immunological support to the respiratory epithelium [2].   
2.1.4 Pathology 
Tracheal injuries and defects are rare. This low incidence has hampered the development of 
definitive surgical protocols for tracheal repair [35].    
2.1.4.1 Types of tracheal insufficiency 
Tracheomalacia describes the condition of having “collapsible” trachea which does not maintain 
its patency, particularly during expiration [36].  In children, it is typically caused by prematurity 
or congenital defects associated with cartilage development.  In adults it is often a consequence 
of prolonged intubation, external compression (for instance, from a tumor), or chronic severe 
infection and inflammation. Surgical stenting is indicated in situations where the defect is not 
intrinsic to the trachea itself. In other situations, no appropriate surgical solution is known.  
Tracheal stenosis describes the condition of having a narrow (yet patent) trachea. “Complete” 
(that is, O-shaped, rather than C-shaped) tracheal rings are the most common congenital cause 
this condition [37].  In adults, stenosis can be iatrogenic, secondary to removal of a long-standing 
tracheostomy tube. In these cases, scar tissue forms over the anterior opening, which contracts 
and narrows the trachea. Alternatively, iatrogenic tracheal stenosis can result from prolonged 
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intubation: high-pressure cuffs (designed to form an airtight seal) can cause ischemia, necrosis, 
fibrosis, and contraction of tracheal tissue [35].    
2.1.4.2 Surgical treatment of short- and long-segment tracheal insufficiency 
When the insufficient tracheal segment is less than a few centimeters, it can be surgically 
corrected via resection and anastomosis. The applicability of this technique has been limited by 
the fact that the trachea is under intrinsic tension in vivo. Significantly shortening the trachea 
adds to this tension, which (1) raises the risk of tissue ischemia and (2) can potentially lead to 
separation of the anastomosis. For these reasons, no more than 25-30% of the trachea’s length 
can be removed [38, 39]. When the stenotic region exceeds this length, surgeons have attempted 
to widen the trachea with an anterior incision closed with a pericardial patch [39].  However, 
these patched tracheas are particularly susceptible to obstruction via granulation tissue formation, 
and must be frequently cleared by bronchoscopy [39].  Further, resection and pericardial 
patching can disrupt the continuity of the epithelium, which can affects the mucociliary elevator 
[40] and the segmental blood supply [4].  
Slide tracheoplasty, depicted in Figure 1, is the preferred treatment for long-segment 
tracheal stenosis [38, 39, 41]. In this technique, a transverse cut is made across the stenotic 
segment of the trachea. The caudal and cranial segments are opened with an anterior longitudinal 
cut and a posterior longitudinal cut, respectively. Finally, the two segments are “slid” against 
each other and are sutured together. The resulting segment has twice the original diameter, about 
four times the cross sectional area, and half the original length [38, 39]. In pediatric patients, the 
resulting segment has been shown to grow over several years [39].   
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Figure 1. Technique of slide tracheoplasty, as diagrammed by HC Grillo [39].  (A) A transverse cut is made at 
the midpoint of the stenotic segment. (B) Anterior and posterior longitudinal cuts are made to widen the caudal and 
cranial segments.  (C) The two ends are anastomosed to each other. (D, E). The widened trachea.   
 
 
 
2.1.4.3 Severe tracheal defects lack an effective surgical solution 
Despite these advances in tracheal surgery, there remains a cohort of patients for which neither 
resection nor slide tracheoplasty is possible. These include pediatric patients with congenital 
tracheal agenesis (with or without an esophageal fistula), and adults with tracheal tumors.  In 
these patients, tracheal transplantation or prosthetic replacement would be a life-saving therapy.   
Tracheal agenesis is rare, occurring in about 1:50,000 births [42].  It may be managed 
temporarily with the insertion of an esophageal tube to provide ventilation to the lungs through 
what remains of the trachea [43]; however, given its low incidence there is no established 
treatment protocol. Mortality approaches 100% and in fact the condition has been described as 
incompatible with life [42].   
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Cancer of the trachea is also rare, occurring in 0.1 per 100,000 person-years. They 
represent about 0.2% of all respiratory tract tumors [44]. These are typically malignant tumors, 
30-40% of which are squamous cell carcinomas associated with smoking. Another 30-40% are 
adenoid cystic carcinomas of unknown etiology [44, 45]. The ten-year survival rate following a 
diagnosis of tracheal cancer is estimated to be between six and seven percent. For patients 
afflicted with these severe tracheal defects, tracheal transplantation could be a curative therapy.  
However, the low incidence of these conditions and the lack of available donor tissues have 
prevented the development of appropriate transplantation protocols.   
2.2 ENGINEERED GRAFTS FOR AIRWAY TRANSPLANTATION 
Given the lack of suitable native tissues, the trachea represents a desirable candidate for repair 
using a tissue-engineered graft. Historically, tracheal transplants have been prepared from 
synthetic or natural materials, using polymeric or decellularized constructs.  Polymeric materials 
have the advantage of being relatively easy to produce in large numbers, and their composition is 
easily controlled. Extracellular matrix is both biomimetic and biocompatible, and in theory 
should be an ideal substrate for tissue repair.  However, neither type of construct in clinical cases 
has been able been able to sustain a cell population which can fulfill the varied design 
requirements of the trachea.   
Over the last decade and a half, several published reports have described tracheal 
transplantation using decellularized and synthetic grafts.  In recent years, many of these reports 
(especially several reports by Maccchiarini and colleagues) have been difficult to interpret  due 
to concerns about data completeness and  integrity and institutional approval and oversight 
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approval [46]. This has left the field of tracheal repair in an uncertain state.  The following is a 
brief overview of human bioengineered airway repair, with a focus on decellularized grafts in 
particular.  
2.2.1 Indications for Tracheal Transplant  
 Tracheal transplantation is indicated for non-resectable causes of airway insufficiency. In adults, 
any lesion less than one-half the length of the trachea can be safely resected; in children, this 
threshold drops to one-third [47].  For patients with smaller defects, slide tracheoplasty can be 
employed to restore the airway [39]. Few options are available for patients with larger defects, 
which can result from congenital causes (long segment tracheal stenosis, tracheal agenesis), 
trauma, or malignancy.  
2.2.2 Decellularized Tracheal Grafts 
A tracheal graft must support a ciliated epithelium and maintain its patency under 
negative pressure. Epithelial cells show improved survival on vascularized surfaces [48], but 
adequate perfusion also remains a challenge in all tissue-engineered constructs (even cell seeded 
ones). The lack of effective perfusion severely limits the size of grafts. Cartilage regeneration is 
particularly important to maintain the patency of implanted grafts. In the human trachea, 
segmental perfusion is provided by microvessels which penetrate the lamina propria, beneath the 
respiratory epithelium [2].   
Bioengineered tracheal transplants have recently been created by seeding decellularized 
native tracheal scaffolds with primary airway cells, mesenchymal stem cells, or some 
 14 
combination of both [49, 50]. The extracellular matrix it thought to provide cells with a three-
dimensional substrate for migration and growth while its molecular composition likely 
influences cell behavior. Molecular signals contained within the decellularized matrix may affect 
rates of engraftment and revascularization, and therefore can be beneficial or deleterious for the 
process of in vivo cellularization.   
2.2.3 Preclinical Research Models for Tracheal Transplantation  
A recent review identified 85 preclinical studies on tracheal repair and regeneration [51]. These 
have been performed in a variety of animal models (mouse, rabbit, sheep, pig and dog), and use a 
number of graft types (decellularized, synthetic, and hybrid). Of these, the rabbit appears to be 
the most popular animal model due to its favorable size (for ease of surgery) and cost. Common 
to all models is the observation that airway repithelialization is a relatively straightforward 
process; however, re-establishment of cartilaginous and vascular cell populations remains 
difficult [51, 52].   
 Decellularized tracheal grafts are prepared using a variety of chemical and physical 
means to remove cellular and immunogenic material from a harvested tissue [51, 53].  
Decellularization protocols vary in length from three days to six months, and typically use cycles 
of detergents, enzymes, and hypertonic/hypotonic solutions to lyse cells and remove them from 
the extracellular matrix. Our published method makes use of a series of vacuum cycles in order 
to increase the ability of these solutions to penetrate the scaffold [1], a version of this approach 
being then adopted by others [54].  Acellular grafts are frequently terminally sterilized via 
gamma irradiation [51]. Many grafts are implanted in the acellular state, but others are seeded 
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with epithelial cells, cartilaginous cells, vascular cells, or some combination thereof and 
incubated in a bioreactor to promote cell adhesion [51].   
We have elected to use the murine, orthoptoic, acellular tracheal graft model due to the 
commercial availability of global mouse knockouts. This technology will allow us to study the 
role of specific genes in airway repair and regeneration. Our experience with decellularized 
mouse tracheal transplants (published in [1], and reproduced in 3.0 on page 34) has demonstrated 
that cell seeding is unnecessary for the establishment of a ciliated epithelium within eight weeks 
of orthotopic transplantation.   
2.2.4 Clinical Use of Tissue Engineered Tracheal Grafts 
A number of research groups have attempted to create engineered tracheal transplants using 
decellularized, synthetic, and hybrid grafts [51, 52]. Despite the publication of clinical case 
reports and subsequent considerable media coverage [55], these engineered tracheas have shown 
limited success in humans, and complication rates remain very high. Published reports have also 
made concurrent use of an omental soft tissue flap to wrap the engineered transplant with to (1) 
provide a source of angiogenic-driven vascularization and (2) create a barrier between the non-
sterile tracheal lumen and the surrounding sterile tissues of the mediastinum [19]. Epithelial 
repair in such decellularized grafts can be described as healing by “secondary intention” -- the 
process by which the surface of the graft is covered with granulation tissue, which is then re-
epithelialized [19].  Indeed, this is the healing process which has been observed in polymeric 
tracheal grafts [20].  While this process generates a functional epithelium, it significantly lowers 
the lumen’s cross-sectional area and the resultant trachea is stenotic. It is thought that re-
epithelialization can prevent iatrogenic stenosis due to scar tissue formation  [20]. Methods to 
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promote rapid re-epithelialization of the luminal surface of the decellularized scaffolds must be 
developed, in order to limit the overgrowth of scar tissue which narrows the tracheal lumen.   
2.3 HUMAN BIOENGINEERED TRACHEAL TRANSPLANTATION 
As mentioned, several groups have attempted to bioengineer human tracheal transplants over the 
last three decades, with the majority of these reports arising from Macchiarini et. al.. Based on 
the currently available data within the public domain, this group reported  17 tracheal transplants 
using decellularized and synthetic grafts between 2008 and 2013 [56].  A review of the current 
state of the field of tracheal tissue engineering would be incomplete without a discussion of the 
preliminary attempts at human bioengineered tracheal transplants, the difficulties associated with 
them, and the implications for the field.   
2.3.1 Catalog of Patients  
Macchiarini et. al. have been involved with at least 17 trachea transplants in the US, Europe and 
Russia between 2008 and 2013. These are briefly summarized in a 2014 article by Jungebluth 
[56], hereafter referred to as the 2014 Review. A full accounting of these patients is difficult, as 
few of these cases generated individual peer-reviewed articles. That this is the case was further 
highlighted in a 2014 news article in Science that also noted the absence of published case 
reports regarding many of these patients and a lack of long-term follow up data [57]. However, a 
review of the literature and popular media reports can be used to provide some albeit limited 
information to begin to catalog these patients and assess their clinical outcomes. A summary of 
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these findings based entirely upon sources within the public domain is represented in Table 1, 
and to the best of our knowledge this is the most complete review of these patients currently 
available.   
The 2014 Review [56] provides only limited information regarding the 17 patients.  For 
each, only the graft type, the indications for surgery, and the status at the time of publication are 
available (in Table 3 on page 104 of that article).  To generate Table 1 below, these patients were 
enumerated (1 to 17) and details in the original table were cross-referenced with available 
literature and media reports. In particular, papers authored by Macchiarini and colleagues 
describing their experience with airway repair and regeneration were used to corroborate and 
expand upon the information in the 2014 Review. The patients were re-sorted by surgical date 
where known. In some cases (in particular, the Russian cases) granting agency databases and 
translated institutional press releases were consulted.   
Given the novel nature of this treatment, these surgeries were frequently accompanied by 
reports in mass media outlets.  In some cases, these sources were consulted to provide context 
and identifying information which could be cross-referenced with the information provided in 
the 2014 Review [56]. Of particular note were the following media sources (1) a  82-minute long 
documentary released in 2014 by NBC News regarding the case of Patient 15 [55] (2) a three-
part question raising documentary investigating Dr. Macchiarini and his work at Karolinska, 
aired by the Swedish television network SVT in early 2016 [58], and (3) a series of news articles 
published in the journal Science [57, 59, 60].  While the SVT documentary is only available in 
Swedish, certain associated articles and videos could be found in English (or in Swedish with 
English subtitles), and these online media items were used as sources to generate Table 1.   
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The three Russian cases were a particular challenge, as they did not generate any peer-
reviewed case reports, and therefore their clinical outcomes are difficult to determine.  Reports in 
European media and Russian government websites indicate that three tracheal transplants using 
synthetic grafts were performed at Kuban State Medical University in Krasnodar during 2012 
and 2013. The 2014 Review [56] states that the authors were the recipients of a “megagrant” 
from the Russian Ministry of Education and Science (identified by its grant agreement number, 
11.G34.31.0065) to perform surgeries in Russia. These three  patients are apparently among the 
17 briefly described in the 2014 Review [56] and correspond to patients 12, 13, and 16 in Table 
1.  Data from two of these patients was presented at a scientific conference in the United 
Kingdom in May 2013 [61].Their identities have been inferred from various Russian and 
Swedish media sources. Of the three, Patient 12 (is the individual whose identity is known with 
the most certainty, as she was closely followed in the SVT documentary [58] (and appeared 
briefly in the NBC documentary [55] describing the case of Patient 15). 
 In August 2014, four colleagues at the Karolinska Institutet1 prepared a document 
analyzing six of Macchiarini et. al. articles on tracheal repair, as part of a complaint filed at the 
Karolinska Institutet [62]. This document was subsequently leaked to the public via the science 
blog RetractionWatch.com in December 2014 [63]. This document describes a number of 
inconsistencies between the patient records of the three individuals treated at Karolinska 
University Hospital and the descriptions of their clinical outcomes in the published literature 
reports. The clinical findings included in the complaint could be used to clarify the outcomes of 
the three Karolinska patients from Eritea, the United States, and Turkey, who are enumerated as 
                                                 
1 In the literature and in media reports, the name of this institution is typically written with its Swedish 
spelling (“Institutet”) rather than the English spelling (“Institute”).  This convention has been maintained herein.   
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Patients 10, 11, and 14 in the table below.  It should be noted that the leaked complaint [62] also 
enumerates the Karolinska patients in chronological order using an independent numbering 
system.  Within that document, 10, 11, and 14 are denoted as Case 1, Case 2, and Case 3 
respectively. 
 The results of these preliminary cases of human bioengineered tracheal transplantation 
have generated significant debate, with implications for the field of tracheal bioengineering. A 
number of recent review articles on tracheal tissue engineering have taken an uncritical approach 
toward these cases, however the reasons for this ae not clear given the substantial perioperative 
morbidity and mortality and long-term complications in these cases [51, 53]. The following is a 
synthesis of peer-reviewed literature and media reports on the controversial surgeries, with a 
focus on a subset of the seventeen patients.  The next section will discuss the consequences and 
implications of the incident for this field (and more generally, clinical translation of tissue 
engineering).   
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Table 1. Trachea Transplants by Macchiarini et al, 2008-2013 
 Nationality Age Indication Type Site of surgery Date  
MM/YY 
Status and date Ref. 
1 Columbia 30 Malacia secondary 
to tuberculosis 
Decell. Hospital Clinic, 
Barcelona, Spain 
06/08 Alive as of 2014 [56, 57, 64-
66] 
2 UK 11 Long segment 
congenital stenosis 
Decell. Great Ormond Street 
Hospital, UK 
03/10 Alive as of 2014 [56, 57, 67, 
68] 
3 Unknown Child <18 T-E fistula Decell. ? ? Died of massive 
bleeding (chest/GI?) 
[56, 57] 
4 Unknown Child <18 Malignancy Decell. ? ? Died, tumor recurrence  
months later 
[56, 57] 
5 Unknown. ? Malacia Decell. ? ? Alive as of 2014 [56] 
6 Unknown. ? Malacia Decell. ? ? Alive as of 2014 [56] 
7 Unknown. ? Malacia Decell. ? ? Alive as of 2014 [56] 
8 Unknown. ? Malignancy Decell. ? ? Died, tumor recurrence   [56] 
9 Unknown. ? Malignancy Decell. ? ? Died, tumor recurrence   [56] 
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 Nationality Age Indication Type Site of surgery Date  
MM/YY 
Status and date Ref. 
10 Eritea 36 Malignancy Synth. 2 Karolinska Inst., 
Sweden 
06/11 Died Jan. 2014. [56, 62, 69-
75] 
11 USA 30 Malignancy Synth. Karolinska Inst., 
Sweden 
11/11 Died Mar. 2012, 
pneumonia? fistula? 
[56, 57, 62, 
70] 
12 Russia 33 “Malacia” 
(Trauma) 
Synth. Kuban State Medical 
University, Russia 
06/12 
 
Died Sept. 2014 [56, 70, 76-
79]. 
13 Russia 28 “Malacia” 
(Trauma) 
Synth. Kuban State Medical 
University, Russia 
06/12 Died in bicycle 
accident. 
[56, 70, 79] 
14 Turkey 22 Iatrogenic malacia Synth. Karolinska Inst., 
Sweden 
08/12, 
07/133 
Remains hospitalized 
as of Jan. 2016 
[56, 62, 80, 
81] 
                                                 
2 The material in this patient’s synthetic graft was polyhedral oligomeric silsesquioxane/poly(carbonate-urea) urethane (POSS/PCU) [69].  Other 
patients receiving synthetic grafts received grafts comprised of polyethylene terephthalate/polyurethane (PET/PU) [62]. 
3 This patient required a re-transplantation. 
 22 
 Nationality Age Indication Type Site of surgery Date  
MM/YY 
Status and date Ref. 
15 Canada 2 Congenital 
agenesis 
Synth. Children’s Hospital, 
Ill., USA 
04/13 Died July 2013. [55-57, 82] 
16 Jordan 42 “Malacia” 
(Trauma) 
Synth. Kuban State Medical 
University, Russia 
08/13 ? [56, 83] 
17 Unknown. ? Long segment 
congenital stenosis 
Synth. ? ? ? [56] 
 23 
2.3.2 Patient Narratives: Decellularized Grafts 
In 2004, Patient 1 presented to the Hospital Clinic in Barcelona, Spain with a tuberculosis 
infection.  The infection was successfully treated with antibiotics over the next six months, but 
she continued to have breathing difficulties. She was diagnosed with post-tuberculosis chronic 
tracheitis, tracheal stenosis, and severe malacia of the left main bronchus. A three-centimeter 
stenotic region of her trachea was resected, and a stent was placed to maintain the patency of her 
bronchus. While the resection was successful, the stent was poorly tolerated and removed.  By 
2008 her condition had worsened and to the point where she was unable to perform basic 
activities of daily living: the diameter of her left main bronchus had been reduced to four 
millimeters by a fixed airway stenosis, and she experienced complete expiratory collapse due to 
her progressing bronchiomalacia [64].   
Patient 1 received a tracheal transplant in June 2008 [57, 64]. Her graft was harvested 
from a human donor and underwent a six week decellularization process referred to as the 
“detergent-enzymatic method.” Twenty-five cycles were performed. During each cycle the 
trachea was washed with distilled water, sodium deoxychoalate, deoxyribonuclease I, and 
sodium chloride solutions to remove cellular material. Bone marrow stem cells (BMSCs) and 
bronchiolar epithelial cells were harvested from the patient and expanded in vitro.  BMSCs were 
differentiated into chondrocytes. The epithelial cells and the chondrocytes were seeded onto the 
graft in a bioreactor and were allowed 24 hours to adhere. An air-liquid interface was established 
by rotating the graft within the bioreactor for three days, after which the graft was transplanted 
into the patient. 
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Over the next several years she would receive a series of stents to maintain the patency of 
her graft [57, 84]. In April 2013, independent journalists seeking to contact the patient were 
unable to do so [57], but at the time of the 2014 Review she was reported to be alive and well 
[56]. Unfortunately her status as of July 2016 is unknown, as no peer-reviewed reports have been 
published about her case since the five-year follow-up in early 2014 [66]. 
In early April 2013, Macchiarini et. al. reported to Science that three children had 
received bioengineered tracheal transplants [57].  This count excludes fourth child, Patient 15, 
who had not yet received her transplant at the time of publication.  Peer-reviewed reports could 
only be found for one, the first, of these children: Patient 2, an Irish boy born with long-segment 
tracheal stenosis.  He received a decellularized transplant in March 2010 [56, 67, 68].   
The second of these children was said to have died due to hemorrhage into her chest after 
receiving a decellularized transplant [57]. This could only correspond to the patient in the 2014 
Review who received a transplant due to a tracheoesophageal fistula and died due to “fulminant 
GI bleeding” [56]. She is enumerated as Patient 3 in Table 1.    
Another child was said to have died due to recurrence of a tumor [57]. The article does 
not specify whether she received a decellularized or synthetic transplant but cross-referencing 
this report with the 2014 Review [56] suggests that she was one of the three patients who 
received a decellularized transplant and died due to “systemic tumor recurrence.” She is 
enumerated as Patient 4.   
Decellularized tracheal transplants were ultimately performed by this group on nine 
patients between 2008 and 2011, including Patient 1 and the three children described above.  
Five of these patients were reported to be alive as of 2014 [51].  This cohort included three males 
and six females. The patients ranged in age from 11 to 72 years. At some time during this 
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process a change in the nature of the transplant was made. Jungebluth and Macchiarni indicate 
that the choice to switch to polymeric grafts as opposed to decellularized natural tracheal tissue 
was driven by concerns over the cost and availability of decellularized tissues of appropriate 
shape, size, and quality [56, 71], and an inability of the decellularized tissues to maintain their 
mechanical integrity when stored or after implantation [57].   
2.3.3 Patient Narratives: Synthetic Grafts 
Patient 10, a 36-year old man, became the first individual to receive a polymeric tracheal 
graft [69, 73]. Patients 11 and 14 followed soon afterwards. All three were treated at Karolinska 
University Hospital between 2011 and 2013. Several patients were also treated at Kuban State 
Medical University in Krasnodar, Russia, but very few details could be obtained on these 
patients.   
Patient 10 was a graduate student at the University of Iceland at the time of his surgery 
[85]. He presented to Karolinska University Hospital with a recurrent primary tracheal 
mucoepidermoid carcinoma which had been unsuccessfully treated at another institution with 
tumor debulking and radiotherapy [69].  He was deemed eligible for a polymeric graft for two 
reasons: first, staging of his tumor [86] indicated that the tumor had not metastasized to distal 
sites [69]; and second, the shape and size of his tumor made resection impossible according to 
existing standards [87].  His graft was comprised of POSS-PCU (that is, polyhedral oligomeric 
silsesquioxane covalently bonded to poly[carbonate-urea] urethane) [69], seeded with bone 
marrow stem cells incubated in a bioreactor for 36 hours. He was also given granulocyte colony 
stimulating factor, filgrastim and epoetin beta following surgery.  His surgery was performed in 
June 2011.   
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The Lancet case report published following his surgery is uniformly positive, stating the 
following:  
There were no major complications, and the patient was asymptomatic and 
tumour free 5 months after transplantation. The bioartificial nanocomposite has 
patent anastomoses, lined with a vascularised neomucosa, and was partly covered 
by nearly healthy epithelium. [69] 
On further review this statement and others were found to be unsupported by clinical records.  
An investigation by the Karolinska University Hospital found several major inconsistencies in 
the 2011 Lancet report and other articles associated with this case [62].  These included clinical 
findings and assessments which could not be corroborated (or were contradicted) by existing 
patient records, a lack of institutional ethical approval, and an informed consent form dated over 
two weeks after the surgery [62].  Patient 10 was readmitted to the hospital 5.5 months following 
transplantation and several days before manuscript publication by Lancet. He would ultimately 
require multiple re-hospitalizations, and was admitted to Karolinska University Hospital for a 
final time in September 2013. Doctors performed 32 additional surgical interventions before his 
death in January 2014 [62]. For unknown reasons none of these clinical details were neither 
disclosed in the original 2011 article [69] nor the follow-up article which was published in April 
2014 [71].     
Patient 11 was a 30-year-old American from Baltimore, MD. Like Patient 10, he suffered 
from cancer which had infiltrated his trachea and received a synthetic tracheal transplant. Unlike 
Patient 10, his transplant was prepared from PET/PU (polyethylene terephthalate/polyurethane). 
His surgery was performed in November 2011 [56, 62, 70]. Very few details are known about his 
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case, as the patient returned to the U.S. from Sweden after his surgery and was apparently lost to 
follow-up until his death in March 2012 [57].  No autopsy was performed. The 2014 Review [56] 
states that he died at home “due to unrelated causes” however the sources of the information 
upon which this conclusion is based cannot be found. When asked about this case,  Macchiarini 
speculated that the patient contracted pneumonia [57]. Others  suggested that Patient 11 likely 
died due to post-surgical complications [57], and in fact claim that this information was relayed 
to the authors Jungebluth and Macchiarini before the 2014 Review was published [62].  The case 
generated no peer-reviewed case reports.  
Patient 14 was a 21-year old University student in 2011 when her trachea was damaged 
during a surgical procedure in her home country, Turkey [80, 81]. As with many other  patients 
described herein, the use of bioengineered tracheal transplants was justified under the so-called 
“compassionate use” concept (what Karolinska University Hospital calls a “vital indication” 
[88]).  In such cases a patient’s grave condition justifies emergency experimental treatment for 
humanitarian reasons [57].  The article which describes her case states the following as a reason 
for her transplant:  
A 21-year-old female patient suffered from an iatrogenic induced severe tracheal 
damage that affected the entire organ. An immediate transplantation was 
necessary to replace the entire trachea with a synthetic based TE tracheal graft 
[81]. 
However, reviewers of her clinical record discovered that she was in no immediate distress. She 
had been released from Istanbul Hospital in October 2011, and was offered a transplant in March 
2012 -- a full four months before her surgery in August of that year [62].  At the time of her 
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surgery, she had been living at home and was stable. The original iatrogenic injury to her airway 
led to coughing fits every few hours, and a Heimlich drain had been placed to drain fluids from 
her right pleural cavity, but she managed her condition from home [62].   
The peer-reviewed article describing her case states the following about the weeks and 
months after her transplant:   
The early clinical evaluation revealed an initial graft epithelialization as judged 
from the 1-week post-operative brushing. The intermediate post-operative 
outcome (5 months) has shown a patent and non-contaminated graft without any 
signs of inflammation.  [81] 
Here also the review of the patient’s records could not confirm these statements. The reviewers 
could not locate clinical reports corresponding to a five-month post-operative time point.  
Bronchoscopies taken three months after surgery describe bacterial infection, and similar 
bronchoscopies 4.5 months after surgery describe granulations and stenting [62]. The patient was 
diagnosed with an iatrogenic tracheo-esophageal fistula 17 days after the first transplantation in 
August 2012. By the time the article was submitted on February 5, 2013 the patient had 
undergone 55 surgical interventions to mitigate complications following her transplant in August 
2012, none of this information appearing in any publications [62].   
As of August 2014, 139 surgical interventions had been performed on Patient 14. These 
include 72 total days of extracorporeal membranous oxygenation (ECMO), seven weeks of 
hemodialysis, 305 total days of ventilator dependency, and re-transplantation using a second 
polymeric graft in July 2013. Bronchoscopies were scheduled every fourth hours, every day, to 
 29 
clear mucus from her airway [62].  By mid-2015, the cost of her continuing care was estimated 
to have reached 60 million SEK, or just under $7 million [80].  
Public reports available in May 2015 indicated that her quality of life has been 
diminished substantially relative to the period after her injury but before her first transplant [80], 
and it remains unclear that her transplant could be justified under the principles of 
“compassionate use” (Karolinska’s “vital indication” standard) [62, 88]. Nearly three years later, 
she remained hospitalized in the intensive care unit at Karolinska University Hospital, awaiting a 
third transplant which she hoped would provide a partial recovery and grant her the opportunity 
to leave the hospital [62, 80]. Her status as of July 2016 is unknown.  
In both the cases of Patient 10 and 14, it appears that the complications associated with 
airway repair using polymeric artificial grafts were known within the first few months after 
surgery. Many of these complications and important surgical details (such as the use of an 
omental wrap) are not forthcoming in the case reports submitted to peer-reviewed journals.  
Nonetheless additional transplants were completed including a notable case in the United States: 
Patient 15 was a Korean-Canadian girl born with congenital tracheal agenesis in August 2010 
[82].  She received a synthetic tracheal transplant in April 2013.  She died three months after her 
surgery, on July 6, 2013, just before her third birthday. Her case was the subject of a NBC News 
documentary in the summer of 2014 [55], which was pulled by NBC following allegations of 
academic fraud and impropriety [89]. 
2.3.4 Post-transplant results 
In late 2014, a complaint [62] filed by four colleagues of P. Macchiarini led to a formal 
investigation. The Karolinska Institutet turned over the complaint to Dr. Bengt Gerdin, a 
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professor of surgery at another university in Sweden. Dr. Gerdin completed his investigation in 
May 2015 and described “a systemic misrepresentation of the truth that leads the reader to have a 
completely false impression of the success of the technique” [59].  He judged Dr. Macchairini 
guilty of scientific misconduct.   
By August 2015, the Karolinska Institutet had received the complaints by Corbascio et al. 
[62], reviewed the “Statement of opinion” from Dr. Gerdin regarding the complaints, and 
considered the non-public responses from Dr. Macchiarini -- and came to the opposite 
conclusion, declaring Dr. Macchiarini “not guilty” of scientific misconduct [90, 91].  
In January 2016, the television network SVT aired a three-part documentary [58] about 
the surgeries, and the American publication Vanity Fair published an article [89] alleging 
academic fraud by Macchiarini (among other charges). The Karolinska Institutet reopened their 
investigation soon afterward [60, 88]. Multiple Karolinska officials involved in the initial 
investigation resigned from their posts in the wake of the renewed public focus on the surgeries, 
including Vice Chancellor Anders Hamsten, secretary-general of the Nobel Assembly Urban 
Lendahl, and Dean of Research Hans-Gustaf Ljunggren [88]. In April 2016, The Lancet 
published a “statement of concern” from the Royal Swedish Academy of Sciences regarding the 
paper which describes Patient 10 [74].  Four authors have asked to be disassociated from the 
article [92, 93].   
In June 2016, Dr. Paolo Maccharini was charged with involuntary manslaughter in the 
deaths of two of the Karolinska patients [94].   
The long-term consequences of the matter are unknowable.  The European Union and the 
NIH continue to fund several tracheal repair projects and trials [95]. Despite global media 
attention, these cases remain generally unknown in the US. The worst-case scenario would likely 
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resemble the fallout following the death of Jesse Gelsinger, which had a chilling effect on gene 
therapy research in the US for a generation [96]. These cases and the subsequent manuscripts 
derived from them, similar to the so-called “STAP” papers of 2014 [97], demonstrate a weakness 
in our scientific method: while peer review can capture errors in logic and data interpretation, 
even the most experienced reviewers are incapable of detecting omitted or fabricated data. 
Thorough and complete documentation and reproducibility of results by multiple separate and 
independent research groups are therefore important in the continued development of 
bioengineered tracheal transplants.   
2.4 CONCLUSIONS 
Tracheal repair and bioengineering of tracheal transplants is a complex undertaking. It is not 
surprising that the preliminary attempts have been frustrated by complications. At this time it is 
not possible to perform a complete, accurate analysis of the existent clinical experience with 
bioengineered tracheal transplantations given the paucity of detailed publications of the known 
cases in refereed scientific journals. However, based on the information found in the public 
domain it is legitimate to conclude that the procedure remains associated with very high 
morbidity and mortality. It is also clear that the field of tracheal bioengineering is in an evolving 
state. Indeed the case has been made that it may be premature to implant tissue-engineered 
tracheas into people. Pierre Delaere and Dirk Van Raemdonck, of University Hospital Leuven 
(Belgium), have been strong critics of the field.  They came to the following conclusion in March 
2016: 
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The engineered trachea was represented as a regenerated trachea after applying 
bone marrow cells to a decellularized or synthetic scaffold. There is no scientific 
foundation whatsoever to assume why stem cells would support airway tissue 
regeneration in this setting. In addition, even if a trachea-like organ would be 
generated, it would irrefutably fail after implantation if adequate blood supply had 
not been restored. As expected, the implantation of decellularized and synthetic 
scaffolds resulted in extremely high morbidity and mortality rates. At this point in 
time, this form of airway regeneration should be regarded as hypothetical and 
scientifically unfounded [98]. 
This view represents an extreme interpretation of the science. Nonetheless, it is prudent to 
reassess the dominant paradigm within the field and given the difficulties encountered with 
present techniques, further basic and translational research is appropriate. The current and 
accepted view has been to provide super-physiologic growth stimulating agents/factors and 
pluripotent and non-pluripotent cell types in huge numbers, the “more-is-better” idea, to enhance 
the healing of engineered transplants, but to no avail. It is reasonable then to re-examine specific 
molecular cues including matrix-cell (matricellular) interactions which inhibit the cellular re-
population and survival of tissue-engineered grafts. Such matricellular interactions may regulate 
angiogenesis and vascularization, cell proliferation, cell survival, or cell turnover.   
Leveraging the power of genetics, our group has developed and published a murine 
model to assess decellularized tracheal grafts to test in mutant mice the role of key matricellular 
signals in tracheal transplantation [1]. Further, I propose that a stress-induced matricellular 
interaction between the secreted protein thrombospondin-1 (TSP1) and its cognate receptor 
CD47 is maladaptively induced during transplantation and functions as a natural, but as of yet 
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unappreciated, barrier to the healing of engineered tracheal transplants. The deleterious effects of 
the TSP1-CD47 signaling axis on cell and tissue survival and angiogenesis under a wide range of 
stress including hypoxia, ischemia/reperfusion, transplant, burn, radiation and heart failure have 
been well characterized by our lab and others [99-112]. The next chapter will describe the 
murine tracheal transplant model. Successive chapters will summarize some of the research on 
TSP1-CD47 signaling in wound healing and regeneration, in order to provide a rationale for the 
work described in this dissertation.  I will also describe our efforts to develop a novel floxed 
CD47 mouse line, for future studies examining the effects of this signaling pathway on specific 
cell populations within a given tissue.   
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3.0  DECELLULARIZED TRACHEAL EXTRACELLULAR MATRIX SUPPORTS 
EPITHELIAL MIGRATION, DIFFERENTIATION AND FUNCTION 
(This chapter has been heavily adapted from our published work, cited here: [1].) 
Tracheal defects or stenosis can result from congenital defects, trauma, or various 
pathologies such as cancer or infection. Partial tracheal loss in patients is debilitating and life-
threatening [113]. In pediatric patients surgical approaches, including slide tracheoplasty, have 
been employed with some success [114]. In adults trachea mobilization has enabled post-
resection repair in select cases. Long-term stenting, dilation, and tracheostomy have also been 
employed as palliative care. However, regardless of the approach complication rates remain very 
high and long term morbidity is common [115, 116]. Also, there remains a cohort of patients for 
which none of the standard approaches can be employed. Therefore, a functional tracheal 
replacement graft is still desirable. 
Initially, engineered tracheal grafts consisted of purified collagen sponges around a stent 
or synthetic scaffold [20, 117]. Although widely studied in pre-clinical models, these have had 
multiple deficiencies. Failure of the first engineered tracheas resulted from several causes 
including infection, stenosis, and complete tissue disintegration [115]. Current engineered 
tracheal grafts and patches are considerably more complex and employ both multiple graft 
modifications and recipient treatments. Common to many is a foundation built upon a 
decellularized tracheal allograft [64, 118]  or a synthetic polymer/nanofiber scaffold [119]  In at 
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least one case, an aortic allograft was employed as the tubular scaffold [120] to provide similar 
structural support. These scaffolds are then seeded with various cell types in order to provide 
functionality, as the size of these grafts limits the degree to which cellular invasion can occur.  A 
number of cell populations have been suggested for reseeding, including basal cells of the lower 
trachea and induced pluripotent stem cells [33]. Scaffolds used in clinical case reports have 
typically been reseeded with autologous airway cells isolated via bronchoscopic biopsy and/or 
chondrocytes differentiated from bone marrow mesenchymal stem cells [49, 50, 64, 84, 118].  
Finally pedicle soft tissue flaps from the abdomen or chest are then wrapped around the 
engineered tracheal transplant to promote angiogenesis, and to sequester the transplant from the 
mediastinum [117]. Recipients may in some cases be treated pre- and post-transplant with 
growth factors in order to maintain the cell population.  Current strategies have shown modest 
success based upon mortality rates, arguably more so with the decellularized allografts than with 
the synthetic scaffolds.   
Despite the publication of clinical reports of transplantation of bioengineered tracheas 
[64, 65, 121-125], the molecular and cellular processes controlling the survival of the tracheal 
grafts remain incompletely defined. We tested the hypothesis that decellularized tracheal 
scaffolds allow cellular invasion/repopulation and functional epithelialization following 
orthotopic transplantation. Employing a murine tracheal transplant model, we report evidence 
that decellularized tracheal scaffolds allow rapid functional cellular restoration and provide a 
rationale for continued development of this technology. 
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3.1 MATERIALS AND METHODS 
3.1.1 Animals 
All animal experiments were reviewed and approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee and were performed in compliance with the Guide for the Care 
and Use of Laboratory Animals as published by the NIH [126]. Age-matched female C57BL6 
mice (approximately 12 weeks old and 20 g in weight) were used in the study, half as donors and 
half as recipients.  Donor tracheas were either immediately transplanted into a recipient or were 
decellularized (with and without vacuum-assistance) and sterilized for subsequent implantation 
as a tracheal graft.  In the first cohort, mice receiving fresh (n=7) or non-vacuum decellularized 
(n=17) tracheal grafts were weighed at regular intervals over four weeks to assess failure to 
thrive in animals during the post-operative period.  Surgeries were performed in groups of two or 
three animals over several sessions. At the end of the study period, specimens were harvested for 
histological analysis and high-quality slides were selected for quantification. Tracheas in the 
second cohort were decellularized with vacuum assistance before transplantation, and surviving 
mice were sacrificed after one or eight weeks. Histologic examination was performed on at least 
four tracheas in each treatment group at both the one- and eight-week time points. At eight 
weeks, three additional specimens underwent fresh video microscopy to examine ciliary beat 
frequency. In three other tracheas microcomputed tomography (microCT) analysis was 
performed.   
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3.1.2 Tracheal Harvest 
Donor animals were anesthetized with an intraperitoneal injection of ketamine (80 mg/kg) and 
xylazine (8 mg/kg), and euthanized by exsanguination. The trachea was exposed through a 
midline neck incision with extension through the proximal sternum.  The trachea was harvested 
from the carina to proximal to the larynx. The larynx was included to facilitate determination of 
proximal to distal orientation of the tracheal graft, which was important for the fresh transplants. 
All tracheas were immediately placed in chilled saline and stored on ice. The fresh transplants 
were prepared for implantation within 15 minutes of harvest.   
3.1.3 Decellularization 
Tracheas were trimmed of excess tissue under a dissecting microscope (Zeiss StemiDV4) and 
were then frozen at -80°C until time for further processing in preparation for surgery. The 
tracheas were thawed in deionized water at room temperature.  Tracheas were then decellularized 
with fourteen 90-minute cycles each consisting of deionized water, 3% Triton X-100, and 3M 
NaCl treatments, leaving a decellularized tracheal scaffold. Tracheas in late cohorts were 
subjected to cyclical pressure changes between room atmosphere and 94% vacuum (6.325 KPa 
absolute pressure) during these washes in a custom apparatus. Vacuum initially degasses the 
scaffold, removing any microbubbles that might serve as a barrier to interactions between cells 
and the decellularization reagents. The cyclical pressure changes are hypothesized to provide 
superior infiltration of detergents and removal of cellular debris. Following decellularization 
scaffolds were disinfected through agitation on a shaker in a 0.1% peracetic acid (PAA)/ 4% 
ethanol solution for 90 minutes at room temperature followed by three 30 minute rinses in 
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phosphate buffered saline (PBS). Scaffolds were then individually packaged in physiologic 
saline, and terminally sterilized by exposure to 20 kGy gamma irradiation.  
3.1.4 Orthotopic Tracheal Transplantation  
Recipient animals were anesthetized with an intraperitoneal injection of ketamine (80 mg/kg) 
and xylazine (8 mg/kg). Animals were placed in a supine position and maintained on a heating 
pad throughout the surgery. The tracheal reconstruction was performed with microscopic 
assistance as described previously [127-130]. The ventral cervical trachea was exposed through a 
midline incision. The graft was then prepared by removing any loose connective tissue from the 
surface and liquid from the lumen, and was cut to a length of five cartilaginous rings from the 
proximal end of the graft. Care was taken to maintain the proximal-distal orientation of the 
grafts, particularly for the fresh transplants. A segment of three recipient tracheal rings was 
dissected from the surrounding connective tissue circumferentially starting approximately four 
rings below the larynx, with care not to damage the recurrent laryngeal nerves. Once the tracheal 
segment was freed, a transverse cut was made in the intracartilaginous tissue until a complete 
transection was performed. A second transection was performed to remove two complete rings of 
the trachea. Meticulous hemostasis was performed through the process. The distal anastomosis 
was performed first followed by the proximal anastomosis.  In both cases, the anastomosis was 
performed with two interrupted 10-0 Prolene sutures placed near the dorsal ends of the cartilage 
rings and one or two sutures placed on the ventral aspect of the tracheal repair. The strap muscles 
were approximated, and the skin incision was then closed with interrupted 7-0 PDS sutures.  
Animals were kept under a warming light and monitored until fully recovered from anesthesia. 
The operative time averaged 20 minutes.  
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3.1.5 Post-operative care 
After surgery, mice were housed in groups of four to five in standard cages, and food and water 
was supplied ad libitum. The following medications were administered as subcutaneous 
injections for five days following surgery: buprenorphine (0.1 mg/kg) twice daily for pain relief, 
gentamicin (8 mg/kg) once daily for infection prophylaxis. At one, four, and eight weeks 
following surgery animals were humanely euthanized with intraperitoneal injections of 
ketamine/xylazine followed by immediate exsanguination, and the tracheas were harvested for 
analysis. For ciliary beat frequency evaluation, animals were euthanized by exposure to carbon 
dioxide and cervical dislocation.   
3.1.6 Histology 
Hematoxylin and eosin staining was performed on decellularized grafts before implantation 
using standard techniques. Briefly, deparaffinization of tissue sections was performed with two 
changes of xylene for three minutes each followed by rehydration in an ethanol series.  Sections 
were exposed to hemotoxylin for two minutes, rinsed with water, exposed to eosin, and rinsed 
with water a second time. Finally, slides were dehydrated with an ethanol series, exposed to 
xylene, and sealed with a cover slip.  Explants selected for immunofluorescence were embedded 
in wax and likewise deparaffinized in two xylene washes, followed by rehydration in an ethanol 
series. Antigen retrieval was performed using 10 mM citrate buffer in double distilled water. 5% 
bovine serum albumin in PBS was used as a blocking reagent.  For the keratin-5 (K5)/keratin-14 
(K14) dual stains, the following primary antibodies were applied: mouse anti-K14 (1:500 in 
blocking reagent) (Thermo/Neomarkers MS-115-P0) and rabbit anti-K5 (1:1000) (Covance 
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PRB-160P). The following secondary antibodies were employed: AlexaFluor 488-conjugated 
goat anti-mouse IgG3 (1:500) (Invitrogen A21151), AlexaFluor 594-conjugated donkey anti-
rabbit (1:500) (Invitrogen A21207). For acetylated tubulin (ACT)/club cell secretory protein 
(CCSP) dual stains, the following antibodies were applied: mouse anti-ACT IgG2b (diluted 
1:20000) (Sigma T6793) and goat anti-CCSP (1:1000) (kindly provided by Dr. Peter Di, 
University of Pittsburgh). These were detected with: donkey anti-mouse IgG (H+L) 594 (1:500) 
(Jackson Immuno 715-485-150), and donkey anti-goat IgG (H+L) 488 (1:500) (Jackson Immuno 
715-515-150). All slides were counterstained with VectaShield Mounting Medium with DAPI 
(Vector Laboratories H-1200). Completed slides were examined with an Olympus IX71 
florescence microscope (Nikon) and the images were captured with Nikon cellSens Dimension 
(version 1.5). A single section from each explant was selected for imaging and quantification.  
Sections were selected for quality based on the orientation of the cutting plane and the integrity 
of the epithelium. Multiple overlapping images were taken of each explant and Adobe Photoshop 
CS5 was used to prepare a photomosaic of all the images from a given slide which allowed 
visualization of the entire trachea. Multiple measurements were taken from each photomosaic for 
quantification. 
3.1.7 Quantification 
ImageJ (NIH, Bethesda, MD) was used to measure the length of several basement 
membrane segments along each explanted tracheal lumen. For each measured segment, DAPI-
stained and antibody-immunolabeled cells along the segment were hand-counted in order to 
determine cell densities (cells/µm). Mean cell densities were calculated for each explanted 
trachea at each time point.   
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3.1.8 Ciliary beat frequency evaluation 
Three tracheas from each treatment group were harvested eight weeks after surgery. Strips of 
tracheal tissue were secured luminal side down on a 35-mm glass-bottomed culture dish (Willco 
Wells, Amsterdam, The Netherlands) using a glass coverslip covered with a silicone sheet 
(0.5mm thick, AAA Acme Rubber Co.) from which a small window had been cut to form a 
shallow chamber. Cilia dynamics were captured at room temperature with a ×100 differential 
interference contrast (DIC) oil objective and a Leica inverted microscope (Leica DMIRE2). 
Movies were captured at 200 frames/s (fps) with a Phantom v4.2 camera (Vision Research). To 
quantify ciliary beat frequency (CBF), ImageJ was used to examine cyclic variations in pixel 
intensities corresponding to the ciliary stroke. More than three randomly selected areas were 
imaged from each trachea in order to calculate mean native and graft CBF for each treatment 
group.   
3.1.9 Ciliary beat axis evaluation 
To quantify variance in ciliary beat axis (CBA), an average of 35 cells were selected in each 
available en face video. ImageJ was used to determine a beat axis for each selected cell, with 
zero degrees representing an axis parallel to the left-right axis of the frame, and 90 degrees 
representing the perpendicular axis. The mean beat axis (between zero and 90 degrees) was 
determined for each video. The degree to which each cell’s beat axis deviated from the video 
mean was calculated.  These deviations were pooled for each animal, and plotted as a histogram.   
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3.1.10 Micro computed tomography 
Three-dimensional image acquisition of explanted tracheas was carried out using a high 
resolution micro-CT (Siemens, Inveon Multimodality, Munich, Germany) at 12 μm image 
resolution at 80 kVe and 500 μm X-ray. 3D surface volume renderings were reconstructed using 
OsiriX software.   
3.1.11 Statistics  
Statistical analysis was performed using GraphPad Prism 6 (GraphPad, La Jolla, CA).  Data are 
presented as mean ± one standard deviation (SD) for each group. For weight change and survival 
analysis, Student’s t-tests and log-rank (Mantel-Cox) tests were performed, respectively. 
Differences in cell counts and ciliary beat frequencies between untreated controls, fresh 
transplants, and decellularized transplants were assessed with two-way analysis of variance 
(ANOVA) with Tukey’s multiple comparisons test. For ciliary beat axis, differences in the 
variance of each distribution were quantified by F-test.  Statistical significance was defined as p< 
0.05.   
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3.2 RESULTS 
3.2.1 Orthotopic tracheal transplantation and decellularized tracheal reconstruction 
rescues mice following tracheal loss.   
Tracheal loss is often fatal, whereas lack of robustly phenotyped pre-clinical models has 
hindered tracheal replacement development  [18]. We tested the hypothesis that orthotopic 
decellularized tracheal transplant alone would rescue mice following full thickness tracheal loss. 
We performed orthotopic transplantation using fresh or decellularized grafts in age matched 
female mice as described (Figure 2a). A summary of the harvested tracheas and analyses 
performed on them is provided in Table 1.  Representative images show excellent healing of the 
fresh tracheal transplant rescuing mice from full thickness tracheal loss (Figure 2b, c). Although 
mortality rates were initially higher for animals receiving the decellularized grafts, particularly in 
the model development phase, they approached those for fresh transplants as experience with the 
model increased. Mortality typically occurred within the first week post-transplant, and was 
generally associated with obstruction secondary to damage to the recurrent laryngeal nerves, 
stenosis, or mucous build-up in the tracheal lumen. Mean weight gain was determined as a 
physiologic relevant marker of overall health. Importantly, surviving animals receiving fresh 
transplants were found to have a 15.1±3.4% increase in weight over the 28-day period following 
surgery (Figure 2c). In contrast to animals receiving fresh transplants, surviving animals 
receiving decellularized grafts experienced an approximate 11% decrease in weight (89.2±16.0% 
of pre-operative weight) during the post-operative interval.   
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Figure 2. Orthotopic transplantation of fresh tracheal grafts is associated with superior recovery post-
operatively.   Orthotopic transplants of fresh and decellularized tracheal grafts were performed on wild-type female 
C57BL6 mice. (a) Still frames from video recording of tracheal transplant performed in a wild-type mouse. Arrows 
denote the site of the tracheal defect (in the first panel) and the transplanted graft (in the second).  (b) Survival 
(fresh: n = 7, decellularized: n = 17, p = 0.165) and (c) weight gain (n > 3 at each time point, p < 0.001 at time 
points denoted with asterisks) over four weeks following surgery shown, for early model development studies. 
 
 
 
3.2.2 Vacuum assisted tracheal decellularization effectively eliminates cells 
We subjected fresh murine tracheas to a range of decellularization cycles (as detailed in the 
methods) during the model development phase. Interestingly tracheas treated with fewer cycles 
displayed the same degree of decellularization as tracheas treated with higher number of cycles. 
Hematoxylin and eosin stains demonstrated total removal of the epithelial layer and no nuclei in 
 45 
the intercartilagenous segments of the tracheal wall, though some nuclear material was 
maintained within chondrocyte lacunae of the cartilaginous rings themselves (Figure 3).   
 
 
 
Figure 3.  Decellularization effectively removes cells from explanted tracheal tissue.   Representative 
hematoxylin and eosin stains from native (a) and decellularized (b) tracheas following 14 cycles of detergent 
osmotic-shock treatment with cyclic pressure changes, as described in this study. Magnification = 20X.  Scale bar = 
50 μm. 
 
 
 
3.2.3 Decellularized tracheal scaffolds display epithelial restoration following orthotopic 
transplantation 
Our finding that decellularized tracheal scaffolds rescued mice from full thickness tracheal 
defects suggested that the decellularized scaffolds facilitated reconstitution of the cellular 
population. Immunofluorescent labeling of fresh and decellularized grafts post-transplantation 
showed complete resurfacing of the internal surface of decellularized grafts by one week post-
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operatively (Figure 4, Figure 5). Time course quantification of cell specific repopulation of the 
tracheal scaffold was performed. Within the first week following surgery, we observed rapid 
repopulation of the luminal surface with a large number of dual-expressing keratin-5/keratin-14 
(K5+/K14+) cells (Figure 4d, h, i). There was no evidence of secretory cells or ciliated cells by 
one week (Figure 5). Over successive time-points the population of K5+/K14+ cells declined 
while the proportion of K5+/K14- and ACT+ cells increased (Figure 4n, o; Figure 5n).   
This same pattern was observed at the anastomotic site in animals receiving the fresh 
tracheal transplant (Figure 4a, e, i). The middle of the fresh transplants showed increased 
numbers of K5+/K14- and ACT+ cells compared with the repopulated decellularized graft.  At 
eight weeks post-transplant the repopulated decellularized grafts contained equivalent numbers 
of K5+/K14+, and K5+/K14+ cells compared to fresh orthotopic tracheal transplants (Figure 4n, 
o). Total numbers of secretory cells per micrometer though initially not significantly different 
from numbers in fresh transplants were decreased in decellularized grafts after eight weeks (Fig. 
Figure 5o). The cartilaginous rings of the decellularized tracheal grafts did not repopulate with 
chondrocytes over the course of the study period (Figure 4, Figure 5, rightmost columns).   
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Figure 4. Histologic quantification of basal cell protein expression in mouse trachea transplants.   (a-l) Mice 
receiving fresh (a, b, e, f, i, j) or decellularized (c, d, g, h, k, l) transplants were sacrificed one (a-d), four (e-i), or 
eight (i-l) weeks following surgery.  Immunofluorescent labeling for basal cell markers keratin-5 (K5, red) and 
keratin-14 (K14, green) was performed, followed by DAPI-staining (blue). Dual-expressing (K5+/K14+) cells are 
indicated in yellow.  Images are shown at a site of anastomosis (a, e, i, c, g, k) or at a mid-graft region (b, f, j, d, h l).  
Arrows denote interface between graft and native tissue; arrowheads denote decellularized graft rings (where 
visible). Scale bar in panel (a) = 100 μm.  (m) Higher resolution image demonstrates prototypical K5+/K14- 
(arrowhead) and K5+/K14+ dual-expressing (arrow) cells. Scale bar = 50 μm. (n, o) Single-positive K5+/K14- (n) 
and dual-expressing K5+/K14+ (o) cells along the basement membrane were counted in order to determine cell 
densities (cells/μm). Columns labeled “Ctrl” denote cell densities for untreated, native trachea from C57BL6 mice.  
Columns with error bars represent mean ± one standard deviation with n ≥ 3 mice in each group.   Pairs of columns 
denoted with an asterisk (*) indicate statistically significant differences (p < 0.05).  Columns denoted with a dagger 
(†) are statistically different relative to the untreated control. Multiple photomicrographs were captured, merged, and 
adjusted for ease of counting.  Magnification = 10X.  Orientation mark given in (d) applies to all images. 
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Figure 5. Histologic quantification of ciliated and secretory cell maturation in mouse trachea transplants.  (a-
l) Mice receiving fresh (a, b, e, f, i, j) or decellularized (c, d, g, h, k, l) transplants were sacrificed one (a-d), four (e-
i), or eight (i-l) weeks following surgery and immunofluorescent labeling for mature epithelial cell markers 
acetylated tubulin (ACT, red) and club cell secretory protein (CCSP, green) was performed, followed by DAPI-
staining (blue). Images are shown at a site of anastomosis (a, e, i, c, g, k) or at a mid-graft location (b, f, j, d, h l).  
Arrows denote interface between graft and native tissue; arrows denote decellularized graft rings (where visible). 
Scale bar in panel (a) = 100 μm. Orientation mark given in panel (d) applies to all images. (m) Higher resolution 
image demonstrates prototypical ACT+ (arrowhead) and CCSP+ (arrow) cells. Scale bar = 50 μm. (n, o) Cells 
expressing acetylated tubulin (n) and club cell secretory protein (o) along the basement membrane were counted in 
order to determine cell densities (cells/μm). Columns labeled “Ctrl” denote cell densities for untreated, native 
trachea from C57BL6 mice. Columns with error bars represent mean ± one standard deviation with n ≥ 3 mice in 
each group.   Pairs of columns denoted with an asterisk (*) indicate statistically significant differences (p < 0.05). 
Columns denoted with a dagger (†) are statistically different relative to the untreated control. Multiple 
photomicrographs were captured, merged, and adjusted for ease of counting.  Magnification = 10X.   
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3.2.4 Cilia function is diminished in decellularized tracheal transplants 
An important feature of the healthy trachea is the ability to handle secretory load and a robust 
coordinate ciliated cell response is a requirement for engineered tracheal transplants. We used 
state-of-the-art real-time microscopic imaging to assess cilia function in our decellularized and 
fresh tracheal transplants and calculate ciliary beat frequency (CBF). We observed the presence 
of functional cilia in both decellularized and fresh orthotopic tracheal grafts. In both fresh and 
decellularized transplant groups, CBF for cells along the graft was not significantly different 
from adjacent native tissue. However, ciliary beat frequency in both fresh and decellularized 
grafts was significantly lower than that of native, untreated trachea (Figure 6b).  
We observed that the ciliary movement in repopulated decellularized transplants 
appeared less uniformly-oriented than in the native tissue.  A mean beat axis was calculated for 
each en face video, and an analysis of the deviations from the mean was performed for each of 
three animals. We observed significantly greater variability in the decellularized graft’s 
repopulated epithelium compared to the adjacent native tissue (Figure 6c).  
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Figure 6. Ciliated cell function of orthotopic fresh and decellularized tracheal transplants. Real time video 
microscopy was employed to quantify ciliary activity eight weeks after transplantation.  (a) A contrast-adjusted still 
frame depicting beating cilia within a decellularized graft is shown; arrowheads denote ciliated cells.  (b) Calculated 
ciliary beat frequencies are shown, with n = 3 mice in each group. Column labeled “Ctrl” denotes ciliary beat 
frequency for untreated, native trachea from C57BL6 mice, based on historical data (n = 41).  Columns denoted with 
a typographical dagger (†) indicate statistically significant differences (p < 0.05) relative to the control column.   (c, 
d) ImageJ was used to examine variability in ciliary beat axis within the epithelium of repopulated decellularized 
grafts.  Shown are contrast-adjusted still frames of decellularized (d) and adjacent native (c) tissue. (e) Distributions 
of ciliary beat axis (relative to mean beat axis) in three mice receiving decellularized grafts. (*) indicates a 
statistically significant difference between the native and graft variances, (p < 0.0001). 
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3.2.5 Tracheal patency is maintained in orthotopic tracheal transplants. 
The current generation of engineered tracheal transplants has been complicated by loss of 
structural integrity and an inability to maintain tracheal diameter [114]. We assessed tracheal 
morphology using micro-computed tomography (Figure 7). Cartilaginous rings were visible as 
radiopaque structures in fresh transplants (Figure 7b), as they were in wild-type untreated 
controls (Figure 7a), but could not be visualized in decellularized transplants (Figure 7c). Both 
the fresh and decellularized transplants experienced a moderate degree of concentric narrowing 
at eight weeks post-surgery. The time course of this narrowing was not immediately clear.   
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Figure 7. Micro-computed tomography analysis of fresh orthotopic tracheal transplants.  Representative 
images shown from computed tomography performed on explanted trachea from wild type, untreated C57BL6 mice 
(a), mice receiving fresh transplants (b), and mice receiving decellularized transplant (c).  Orientation in (a) applies 
to all images.  Arrows in (c) denote the boundaries of the decellularized graft. 
 
 
3.3 DISCUSSION 
The present study showed quantification and functional assessment of the first ever murine 
model of orthotopic decellularized tracheal transplant. Although more technically challenging 
than established the heterotopic transplantation models, the orthotopic model carries a reduced 
risk of luminal obliteration [127].  Further, orthotopic transplantation provides the opportunity to 
observe physiologic healing via epithelial migration and proliferation from native tissue adjacent 
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to the anastomosis site. Most important, it mimics the clinical situation and demands functional 
responses from the transplant if the animal is to both survive and thrive.  
A wide variety of techniques have been proposed to decellularize tissues and organs, 
including chemical, enzymatic, and mechanical [49, 131]. In this study, decellularized trachea 
processed with Triton X-100, 3M NaCl, deionized water, and 0.1% peracetic acid supported 
rapid cellularization with epithelial cells on the lumen of the graft and mesenchymal cells within 
the parenchyma of the scaffold.  By eight weeks, the lumen was covered with a site-appropriate 
pseudostratified epithelium with ciliated cells and secretory cells present.  By eight weeks, the 
epithelium showed motile cilia, although the ciliary beat frequency was less than a native mouse 
trachea, and showed variations in the orientation of ciliary movement as compared to the normal 
synchronized beating found in the native trachea.  Analysis of longer time points will determine 
if ciliary function normalizes in transplanted grafts.    
The trachea is potentially an ideal candidate for repair using a decellularized graft. A 
mature epithelium in particular is a necessary component of any tracheal graft, in order to (1) act 
as a barrier defense and (2) to provide mucociliary clearance. It has been reported that a 
confluent epithelial layer can reduce or even prevent fibrosis and subsequent stenosis of a 
tracheal graft [20, 117]. To promote the development of an epithelial layer, decellularized 
tracheas are frequently seeded with epithelial cells, and cartilaginous rings are repopulated with 
chondrocytes derived from bone marrow stem cells. Such grafts have been shown to maintain 
some cell population during the recovery period [84, 118, 132]. Further, decellularized matrix 
derived from porcine tracheal tissue promotes re-epithelialization in a canine model of patch 
tracheoplasty [133, 134]. Porcine decellularized tracheal tissue grafted into pigs and mice in 
heterotopic models showed no immune rejection [135]. These findings suggest that the 
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decellularized matrix provides an appropriate substrate for epithelial migration, differentiation, 
and function.  
The native tracheal epithelium is complex and is composed of heterogeneous cell 
populations, some of which act as progenitor cells [30, 136, 137].  Although multiple studies 
have included histologic evaluation of tracheal allografts following transplantation, none have 
examined invasion, proliferation and regression of various populations of basal cells over time. 
Herein, we examined the kinetics of epithelial healing and quantified the spatiotemporal rate of 
epithelial repopulation via immunofluorescent labeling. We observed complete resurfacing of the 
decellularized tracheal lumen by the end of the first week post-transplant, following early 
proliferation of K5+/K14+ basal cells. Previous studies have demonstrated that K5+/K14+ basal 
cells represent a precursor cell population with the capacity to develop into ciliated (ACT+) and 
secretory (CCSP+) cells [24, 136]. This finding is supported by our histological data, which 
shows a correlation between the depletion of the K5+/K14+ cell population and the generation of 
a mature differentiated epithelium (Figure 4, Figure 5). Similarly, in animals receiving fresh 
transplants, the presence of K5+/K14+ cells near sites of anastomosis suggests that this cell 
population plays a role in epithelial healing (Figure 4a).   
 Histologically, we observed that cartilaginous portions of the decellularized trachea 
remain acellular throughout the course of the 8 week healing period, while chondrocytes within 
the fresh tracheal transplants appear to be   maintained.  Computed tomography (Figure 7) did 
not demonstrate radiopaque cartilaginous rings within decellularized grafts after eight weeks, in 
contrast to fresh transplants.  Scans performed on decellularized grafts before transplantation 
similarly demonstrated a lack of visible radiopaque cartilage (data not shown). These findings 
suggest that cartilaginous rings lose their molecular structure during the process of 
 55 
decellularization, and are not repopulated after transplantation. Despite the presumptive loss of 
mechanical structure associated with the degradation of the cartilaginous rings, decellularized 
tracheal grafts maintained their patency over eight weeks. Additional studies will assess 
chondrocyte viability and repopulation in orthotopic transplants.  
 The present study had a several limitations. First, the murine orthotopic tracheal 
transplant is technically challenging, and these challenges contributed to the decreased post-
operative survival observed in the early model development studies. The technical challenges 
involved in the surgery were mitigated with experience, as demonstrated by the improved 
survival seen in later cohorts. Second, histologic analysis was limited by the selection of time-
points. Rapid re-population of the luminal surface of each tracheal graft prevented observation of 
basal cell behavior within the first week, during the period of initial proliferation. This will be 
addressed by the addition of early time points in future studies. Third, the diameter and cross 
sectional area of the decellularized tracheal grafts could not be assessed via computed 
tomography, as originally predicted. We hypothesize that exposure to peracetic acid and/or 
gamma irradiation during the decellularization process disrupts the molecular structure of the 
cartilaginous rings, making it difficult to identify the lumen of each graft via microCT. Given 
that the cartilaginous rings maintain the structural integrity of the trachea and patency is an 
absolute requirement for a tracheal graft, the functional consequences of this loss of cartilage 
must be further investigated. Further, we observed moderate narrowing of the decellularized 
tracheal explants which could be secondary to this loss of cartilage.   
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3.4 CONCLUSIONS 
These data demonstrate the potential for an orthotopic murine tracheal transplant model to be 
performed for the evaluation of decellularized grafts. The data presented suggest this model is a 
reliable pre-clinical platform for research. The use of mice will allow for the procedure to be 
economic and efficient. This model will also allow for harnessing the power of mutant murine 
models to test the role of specific genes (in knock out or over-expressing strains) in the process 
of matrix restoration and tracheal transplant healing. The role of innate and acquired immunity in 
the setting of tracheal transplantation may also be investigated by applying this technique to 
several well characterized murine systems of immunologic activation.   
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4.0  THROMBOSPONDIN-1 (TSP1) AND CD47 IN HEALTH AND DISEASE 
The thrombospondin-1 (TSP1)-CD47 signaling axis represents a key cell-matrix interaction 
which may regulate repopulation of decellularized grafts through its effects on cell survival, self-
renewal, and angiogenesis. TSP1 is a secreted protein upregulated after injury and in response to 
hypoxia and tissue stress.  Prior research has demonstrated that TSP1 binding to and activation of 
receptor CD47 hinders the survival of cells and whole tissues under stress [138].  
The role of TSP1-CD47 signaling in direct regulation of the airway epithelium is unclear.  
Literature reports indicate that TSP1 is highly expressed by humans airway basal cells in in vitro 
culture conditions [21].  At least one study also demonstrates that TSP1 null mice have greater 
club cell repopulation after naphthalene injury [139]. These findings support the role of 
matricellular proteins in regulating cell behavior, and highlight the potential role matricellular 
proteins may play in decellularized grafts. This informs my hypothesis that TSP1, via 
interactions through cell-surface receptor CD47, inhibits cellular survival, engraftment, 
and revascularization of decellularized tracheal grafts.   
The following sections will provide some background on TSP1 and CD47, will describe 
the TSP1 null and CD47 null phenotypes, and will give some details on TSP1-CD47 signaling in 
health and disease. Finally, this chapter will describe our efforts to develop a floxed CD47 
mouse line for future studies examining the role of CD47 signaling in specific cell populations 
within tissues.   
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4.1 THROMBOSPONDIN-1 (TSP1) 
The thrombospondins are founding members of a class of molecules known as matricellular 
proteins [140]. These molecules reside in the extracellular matrix, but provide no structural 
support.  Thrombospondin-1 (TSP1) in particular is a 420 kDa protein which is assembled from 
three identical polypetides. Each polypetide is 1152 amino acids in length, which is cleaved from 
an 1170 amino acid precursor. The three peptides are joined via disulfide linkages near their N-
terminal end.   
The structure of TSP1 is highly conserved in the mammalian genome, with 95% 
homology between mouse and man in terms of sequence and exon distribution [141, 142].  
Murine Thbs1 and human THBS1 are both about 16 kilobases in length, with about 6 kilobases of 
exons [141, 142].  Many literature reports prefer the shorter acronym, TSP1, to refer to the 
protein itself.   
4.1.1 Structure 
Each of the three TSP1 peptides is modular, and contains sequences which are named for their 
resemblance to other known proteins [141]. These regions include an N-terminal domain, a 
procollagen-like domain, three sets of “repeat” motifs (termed type 1, 2 and 3), and finally the 
carboxy-terminal domain. A schematic is shown in Figure 8. Like other matricellular proteins, 
TSP1 functions through binding to multiple molecules including matrix such as collagen and cell 
membrane proteins [143]; a study of the TSP1 interactome identified 83 interacting partners 
[144], a number of which are described below. It is important to emphasize however, that ligand 
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binding affinities for these interactions have only been published in a few specific cases, and thus 
use of the term ‘binds’ implies interacts with.  
The N-terminal domain binds to a number of extracellular matrix proteins including 
aggrecan and heparin [144] and the calcium binding protein calreticulin [145].  Three “Type-1” 
repeats bind TGF-β, MMP2, MMP9, laminin, and fibronectin in the matrix and to CD36 and β1 
integrins on cells [141, 144]. TGF-β in particular is activated by TSP1, while TGF-β signaling 
can stimulate the production of TSP1 [146, 147]. TSP1 binding to β1 integrins inhibits cell 
migration [148].  Three Type-2  (“EGF-like”) repeats bind β1 integrins [141, 144].  Seven “Type 
3” repeats are noted for their interactions with calcium ions [141]; the last of these contains an 
RGD sequence which binds readily to αvβ3 integrins [141]. Finally, the carboxy-terminal 
domain is primarily notable for its high-affinity interactions with the cell membrane receptor 
CD47.  Of all its binding partners, TSP1 appears to have the most affinity for CD47, which it 
activates at picomolar concentrations [141, 144].   
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Figure 8. Schematic of the secreted glycoprotein thrombospondin 1 (TSP1).  TSP1 is a homotrimer, with three 
identical monomers linked together via a disulfide knot. Figure demonstrates the locations of the type 1 (I), type 2 
(II) and type (III) repeats within the chain. CD47 binds to the carboxyterminus. A nearby VVM sequence may be 
important for TSP1 binding to occur. Original figure created by author, adapted from [141].   
 
4.1.2 TSP1 in Development and Adult Tissues 
TSP1 is expressed highly in a variety of developing tissues, including the lung, bone, brain, 
heart, liver, and kidney [149, 150]. Its expression is often associated with specific cell 
populations within a tissue. For instance, TSP1 is highly expressed in mesenchymal cells as they 
differentiate into osteoblasts [151], and low levels of expression are associated with 
chondrogenesis [149]. During lung development, TSP1 is observed along the basement 
membrane in the columnar epithelium of the large airways [151]. 
Within the adult, TSP1 is most well-known for its localization within the alpha-granules 
of platelets, and is released upon platelet activation [112, 141]. The remainder decorates the 
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extracellular matrix of various tissues. It is produced by a variety of cell populations (epithelial, 
stromal, and endothelial) under stress [112]. 
4.1.3 TSP1 in Clinical Disease 
In systemic sclerosis, tissue levels of TSP1 are correlated with fibrosis and disease severity [140, 
146, 152]. This is thought to be due to TSP1 activation of TGF-β. TSP1 has also been 
investigated as a biomarker for metabolic syndrome [153, 154], stroke severity [155, 156], and 
peripheral artery disease [157]. TSP1 has also been found to be upregulated in sickle cells 
disease and associated with some vasculopathic changes in these individuals (cite Novelli et al, 
PMID: 22318901 and Rogers et al, PMID: 25006410) 
TSP1 has been implicated in the pathological vascular remodeling process which occurs 
in pulmonary arterial hypertension [158]. Hypoxia induces TSP1 production via HIF2α [159].  
TSP1 has also been implicated in kidney disease (specifically, renal epithelial cell self-renewal 
[100, 103, 160] and kidney fibrosis [161, 162]). Many, if not all, of these effects are mediated 
through TSP1 ligation of CD47, which is described in more detail below.  
4.2 CD47 
4.2.1 Structure and Localization 
CD47 is a widely-expressed 50 kDa transmembrane protein, once known as integrin associated 
protein (IAP) due to its tendency to co-precipitate with placental αvβ3 integrin [163].  Its N-
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terminal extracellular domain is an immunoglobulin-like loop. It has five transmembrane 
sequences and a short cytoplasmic tail [163].  The structure of CD47 is well-conserved. Murine 
CD47 is 71% identical (and 87% “similar”) to its human counterpart [163].    
Intracellularly, four CD47 isoforms have been described, which differ only in their 
localization and the length of their cytoplasmic tail [164]. The shortest, Form 1, is four amino 
acids in length; the longest (Form 4) is 34 amino acids in length. Of these, Form 2 is the most 
widely expressed.  The sequences of the four isoforms are highly conserved between mouse and 
man, but their significance remains unknown [164].  CD47 has been observed to associate with a 
variety of other cell-surface proteins to form a supra-molecular complexes in different cell 
populations, and it is possible that these splice isoforms are partially responsible for this 
phenomenon [111].  
4.2.2 Signaling and Function 
Historically, CD47 has been considered a marker of self which ligates with SIRPα on 
macrophages and prevents phagocytosis, termed a “don’t-eat-me” signal [111, 165].  In this 
regard, CD47 has been investigated as a target for anti-cancer [166-168] and anti-atherosclerotic 
[169] immunotherapy. This finding has further encouraged the development of CD47-
functinonalized biomaterials and xenografts to modulate immune responses [170, 171].  
However, the relevance of this is called into question by studies that found that CD47 null tissue 
transplants survived and flourished when transplanted into wild type animals, outperforming 
wild type transplants into wild type recipients [107]. Others have suggested immune responses 
attributed to CD47 recognition of self are non-specific [172, 173]. Thus, the implications of the 
so-called “don’t-eat-me” signal in relation to human disease are not clear. Far from being a 
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passive protein, CD47 is in fact a component of a number of signaling pathways involved in 
tissue survival.  These signaling pathways are reviewed briefly below. 
Although CD47 has been shown to interact with TSP2 and TSP4 at lower affinity, TSP1 
is its only known soluble high-affinity ligand [174].  A VVM sequence on the C-terminal end of 
TSP1 is thought to be important  for its ability to bind to CD47 and modification of this sequence 
abolishes the interaction between these two proteins [175], even though the VVM motif itself 
does not appear to be directly involved in binding [111].  Heparin sulfate glycosylation of the 
extracellular domain of CD47 at Ser64 seems to be necessary for TSP1-CD47 signaling to occur 
in certain cell types such as T-cells [111, 176].   
 CD47 is thought to signal through a variety of pathways which vary depending on cell 
type [111].  It has been observed to associate with the cytoskeleton via PLIC-1 (also known as 
ubiquilin) [177], and, in doing so, signals through a non-canonical G-protein pathway [178, 179].   
Its extracellular IgV domain has been shown to laterally associate with a number of integrin 
populations, but most specifically αvβ3 [180].  CD47 has also been shown to laterally associate 
with VEGFR2 in endothelial cells. TSP1 ligation disrupts this association, and in doing so, 
inhibits VEGFR2 signaling and several downstream pathways including putatively nitric oxide 
(NO) signaling [112, 181]. Independent of its interaction with VEGFR2, the TSP1-CD47 axis is 
a redundant limiter of nitric oxide. In endothelial cells TSP1 signaling inhibits the activation of 
endothelial nitic oxide synthase and thus limits NO production (Bauer et al, PMID: 20610415). 
In multiple vascular cell types the TSP1-CD47 axis also inhibits NO activation of soluble 
guanylate cyclase [182-184].  Given the critical role of nitric oxide signaling in cardiovascular 
health, TSP1 ligation of CD47 has broad implications [112, 184, 185].   
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4.3 TSP1-CD47 SIGNALING IN TISSUE SURVIVAL 
We and colleagues have reported that the TSP1-CD47 axis is a redundant inhibitor of multiple 
angiogenic and survival signals including the biogas nitric oxide (NO) and vascular endothelial 
growth factor (VEGF) [181, 186]. Upregulation of the TSP1-CD47 axis impairs healing of skin 
grafts in mice [107] and ischemic soft tissue flaps in pigs [106]. Lack of CD47 activation by 
TSP1 in null mice significantly reduces necrosis/apoptosis after ischemia-reperfusion injury in 
the liver, kidney, and brain [99-105] and limits radiation-induced cell death [108-110]. Targeting 
the TSP1-CD47 interaction with CD47 specific antibodies or morpholino oligonucleotides, to 
suppress protein production, improves tissue healing to ischemia, ischemia reperfusion and organ 
transplantation. Significantly, CD47 activation has also been shown to inhibit protein and mRNA 
levels of c-Myc and other key self-renewal factors including Klf4, Sox2 and Oct4 [187].  This 
observation has been identified as a likely mechanism for improved healing after kidney 
ischemia reperfusion injury [103].   
4.4 TSP1 NULL VERSUS CD47 NULL PHENOTYPE 
CD47 null mice, like TSP1 null mice, are available from the Jackson Laboratory [188, 189].  The 
CD47 null mouse was created via elimination of exon 2 [190].  It is known to be susceptible to 
certain infections such as E. coli due to deficits in neutrophil trafficking [190].  Phenotypic 
differences between the TSP1 null mouse and the CD47 null mouse are likely secondary to their 
interactions with different binding partners [111].  CD47 null and TSP1 null mice show greater 
numbers of healthy mitochondria and lower levels of reactive oxygen species relative to wild-
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type mice [191].  Mice of both genotypes also show resistance to radiation injury [108, 110], and 
both show improved skin graft survival relative to wild type recipients [107].  Both also show 
similar cardiovascular physiology and increased sensitivity to isolflurane anesthesia due to the 
effects of TSP1-CD47 on nitric oxide signaling and blood pressure regulation [192].   
Hemotologically, TSP1 null mice have greater white cell counts than their wild-type 
counterparts [149]. There is some dispute as to whether or not TSP1 null mice and wild type 
mice have similar platelet counts; early literature reports suggested that the two populations have 
comparable counts [149] whereas later reports indicate suggest that TSP1 null mice have about 
22% more platelets [147]. As expected, platelet α-granules do not release TSP1 upon activation.  
TSP1 null mice have an increased lordotic curvature of the spine [149] and increased bone mass 
[193].  In contrast, CD47 null mice show decreased bone mass and lower numbers of osteoclasts 
and osteoblasts, a phenotype which is thought to be due to a lack of SIRPα signaling [194], while 
other have found the opposite (cite Uluckan et al, PMID: 19276363). The TSP1 null mouse is an 
accepted model of Sjorgen’s Syndrome [189, 195].  
Histologically, the adult TSP1 null mouse is very similar to the wild-type mouse, 
suggesting that other signaling pathways can compensate for its role during development [149].  
There are a few notable exceptions: TSP1 null mice have normally-developed lungs, but show 
increased susceptibility to pneumonia and hyperplasia of the airway epithelium, largely due to a 
greater number of club cells [149].   
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4.5 DEVELOPMENT OF A FLOXED CD47 MOUSE LINE 
Global knockouts are of some utility in cell signaling studies. They can be employed to 
characterize systemic phenotypic differences, but studies of organ-specific, tissue-specific, and 
cell specific differences require a more precise approach.  An induced knockout could be 
employed to identify phenotypic differences which are independent of development. The 
ubiquitous expression of CD47, and its wide range of downstream effects, make it an interesting 
scientific and therapeutic target. A cell-specific knockout may therefore useful to examine 
consequences of cell-specific CD47 therapy. Further, cell-specific knockouts could be used to 
determine exactly which cells within a given tissue are responsible for TSP1-CD47 signaling. 
To this end, we have sought to derive a mouse line in which critical CD47 exons are 
flanked by loxP sites. This mouse, when bred with a Cre expressing mouse, wound undergo 
recombination which leads to production of incomplete CD47 protein. Cre-expression can be 
constitutive or inducible, cell-specific or global. Each of these expression patterns correlates with 
a different pattern of recombination, and each would elucidate of different aspects of CD47 
signaling.  A floxed CD47 mouse would therefore be an invaluable resource to scientists which 
aim to study the role of TSP1-CD47 signaling in specific cell types within tissues after 
development.  
To complete this task we have exploited the resources of the Knockout Mouse Project 
(KOMP), an NIH-funded, nationwide effort to develop mouse knockout strains and make them 
available to scientists in the United States and worldwide [196].  KOMP collaborates closely 
with the International Knockout Mouse Consortium (IKMC), which coordinates publicly- and 
privately-funded projects worldwide. The following is a summary of the history of the IKMC 
and its aims.   
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4.5.1 Background 
A large-scale, genome-wide knockout mouse project was first proposed in 2003 with the aim of 
developing knockout mouse resources for laboratory investigators. Curated databases at the time 
only described global knockout mice in about one-tenth of 25,000 estimated mouse genes [197].  
Many of these resources were unavailable for public use. In light of this a worldwide, systematic, 
centrally-curated initiative to mass-produce knockout mouse lines could provide investigators 
with a vital resource.  These mice could be used to generate previously-unavailable experimental 
models and, in doing so, advance biomedical research.  
The 2003 working group (whose proceedings are summarized in a 2004 publication 
[197]) promulgated the following guidelines for the initiation of such a project: (1) a variety of 
methods (e.g., both gene trapping and gene targeting [198, 199]) should be employed in order to 
mass-produce null alleles, (2) null alleles should include reporter sequences in order to expedite 
the process of cell and tissue phenotyping for end-users, and (3) at a minimum, the project 
should produce, bank, and make available mutant ES cells to researchers across the country and 
around the world [197].  The authors recommended against the use of cis-elements (such as loxP 
or FRT sites) which could be used to generate conditional knockouts, due to the nascent state of 
the technology at the time.   
Austin et al. [197] further described several tiers of phenotyping which could be centrally 
provided by the project. Once the absence of a particular gene in a particular mouse line has been 
firmly established, Tier 1 phenotyping would be employed to elucidate certain aspects of the 
mutant mouse’s physiology (for instance, blood chemistry and hematological profiles).  
Microarray transcriptome analysis would identify a subset of mice for deeper, system-specific 
examination. At the time, it was estimated that a majority of mouse genes could be knocked out 
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within five years, at a total cost of about $50 million (about $10 million per year). Production of 
500 new mouse lines from the mutant ES lines was estimated to cost $12.5-15 million annually.  
Tissue of these 500 lines was expected to cost up to another $5 million (for tissue phenotyping), 
with another $2.5 million for Tier 1 phenotyping and another $18,000 for each mouse line 
selected for transcriptome analysis. 
Critics of such large-scale projects raised concerns about the scope and scale of the 
project, citing insufficient demand for many of the commercially available knockout lines which 
were available at the time [200]. Further, given that many phenotypes are driven by multiple 
genes and redundant signaling pathways, single-gene knockouts may not alter physiology in a 
clinically meaningful way.   
In spite of this, not one but four genone-wide knockout mouse projects have arisen in the 
years since the 2003 working group [199]: one in Europe (EUCOMM), one in Canada 
(NorCOMM), and two in the United States (the NIH-funded Knockout Mouse Project [196] and 
the state-funded Texas Institute for Genomic Medicine). The International Knockout Mouse 
Consortium (IKMC) was established in 2006 in order to limit redundancy and encourage data 
sharing between these four groups and any others willing to undertake the task [196, 199, 201].   
4.5.1.1 Allele Types and Allele Conversion  
Austin et al. [197] describe several deliverables for the knockout mouse project, 
including gene trapping constructs, frozen zygotes, frozen embryos, live mice, and phenotypic 
data. Critical to all is the development of an allele which can be easily modified via 
recombination using Cre-lox or FLP-FRT recombination.  
KOMP has developed a generic allele design for this purpose known as the tm1a allele 
[201].  It is based on the “knockout-first” allele design described by Testa et al [202]. A tm1a 
 69 
homozygote is a complete knockout (due to the presence of two SV40 polyadenylation 
sequences which prevent transcription of the entire gene). A tm1a mouse is the “first” step in a 
breeding strategy to derive a floxed allele (hence the name, “knockout first”). Recombination of 
the tm1a allele using Cre or FLP-FRT technology yields further alleles. The tm1a allele and its 
derivatives are diagrammed in Figure 9. 
 
 
 
 
Figure 9.   Allele maps and recombination strategy for the tm1a allele. Figure made by author, adapted from 
[203].   
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The tm1b lacZ-tagged allele is generated when the tm1a allele undergoes Cre 
recombination [201].  Ideally, this process removes all genetic material between the most 3’ and 
5’ loxP sites in the tm1a sequence, including the neo sequence, both poly-adenylating sequences, 
one or more targeted exons, and one of the FRT sites. Mice which are homologous for tm1b 
should also be complete knockouts.  (In practice, Cre recombination can remove genetic material 
between any two of the three loxP sites in the allele – not just the most 3’ and 5’ sites.  This 
means that two additional alleles can be generated in addition to the desired tm1b allele: one 
which lacks the neo sequence only, and the other lacks targeted exons only. In these cases, the 
allele is designed so that the recombination process creates a frameshift mutation which 
phenotypically resembles a knockout [201].) 
The tm1c allele is generated when the tm1a allele undergoes FLP/FRT recombination, 
which excises all genetic material between the two FRT sites, including both polyadenylation 
sequences [201]. This recombination reverts the cell to a wild-type phenotype, and it should 
generate a normal protein. In particular, it should be noted that this recombination leaves two 
loxP sites on either side of the target sequence which can be targeted with Cre recombination; 
thus, a mouse homozygous for tm1c is a traditional “floxed mouse.”   
Finally, Cre recombination of the tm1c allele yields the tm1d allele, which should not 
express normal protein. Like the tm1a and tm1b alleles, and the tm1d allele represents a 
“knockout” genotype and phenotype.   
The tm1a allele for the CD47 gene was originally developed by the Knockout Mouse 
Project [203].  It should be noted that the target sequence of the CD47 tm1a allele includes exons 
2 and 3 [203], whereas the commercially available CD47 null mouse was generated via the 
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removal of exon 2 only [188, 190]. The physiological implications of this difference are not 
completely known, however cell-specific analysis suggest the lack of exons 2 and 3 phenocopies 
gene expression patterns found in cells from the commercial CD47 null mice.   
4.5.2 Methods 
We aimed to generate a mouse line which (1) is homozygous for a floxed CD47 allele and (2) 
expressed CD47 in the absence of Cre. A tm1a+/+ mouse population would not fulfill these 
criteria. (Once again, even though the tm1a allele contains loxP sites, the allele does not express 
CD47 due to the polyadenylation sites within its sequence – hence the term, “knockout-first” 
[201]). We genotyped mice at every step of the process, and in early generations, assessed for the 
expression of CD47. Genotyping was initially performed using in-house protocols based on 
information provided by KOMP; however, as litter sizes increased we elected to outsource this 
task to Genetyper (NY) which specializes in this work.   
4.5.2.1 Breeding Strategy 
The breeding strategy we developed was designed to derive a tm1c+/+ mouse line from 
tm1a+/- breeding pairs.    
It is summarized immediately below, diagrammed in Figure 10a on page 77, and is 
described in detail in section 4.5.3. It should be noted that the tm1a and Flp alleles both contain a 
neo sequence, as indicated in Figure 9. Mice were assayed for the neo sequence during later 
generations to establish that both the tm1a and Flp alleles had been cleared from the tm1c mouse 
line. This is discussed in more detail in the extended description of the breeding strategy below 
(see 4.5.3.3).   
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1. Founder Generation: tm1a+/- x tm1a+/-, which yields tm1a+/- mice 
2. Generation 1: tm1a+/- x tm1a+/- sibling mating, which yields tm1a+/- mice 
3. Generation 2: tm1a+/- x Flp+/+, which yields (tm1a+/- Flp+/-) mice.  These undergo 
recombination to become (tm1c+/- Flp+/-) mice.  
4. Generation 3: (tm1c+/- Flp+/-) x C57BL6J, which clears the Flp allele 
5. Generation 4: tm1c+/- x tm1c+/-, which produces the floxed mouse (tm1c+/+) 
 
4.5.2.2 Genotyping 
We obtained primer sequences from KOMP (via our collaborator Dr. William Fazier) and 
the Jackson Laboratory to genotype each litter.  For our in-house genotyping, these primers were 
synthesized by Integrated DNA Technologies (Coralville, IA).  
In-house genotyping was found to be inefficient.  Large litter sizes necessitated extended 
downtime (about one week every month). To increase efficiency, we employed the resources of 
Genetyper, a dedicated genotyping service.  Genetyper synthesized their primers based on our 
provided sequences.  The primer sequences provided to us are listed in Table 2. The primer pairs 
used to genotype each allele are summarized in Table 3. Cycling parameters for Flp and tm1a 
genotyping are provided in Table 4 and Table 5, respectively.  
4.5.2.3 Western Blot Analysis  
Western blots were employed as an assay of CD47 phenotype. Detailed descriptions of 
the standard Western blotting protocol used are available in 6.1.10, on page 100.  Briefly, protein 
lysates were centrifuged at 17000 x g and supernatants were kept frozen until analysis.  Samples 
were prepared under nonreducing/denaturing conditions, were run on acrylamide gels, and 
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transferred onto nitrocellulose membranes. A rat-anti-mouse CD47 antibody (clone MIAP301, 
Santa Cruz sc-12731, 1:500) in LiCor Odyssey Blocking buffer was used to detect CD47. 
Detection of CD47 required that the blots be incubated for 48 hours in the primary antibody, on a 
rocker, at 4 oC.  Rabbit anti-beta actin 1:5000 (Cell Signaling 4967) was used as a loading 
control. These were coupled with appropriate secondary antibodies. 
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Table 2. Primer sequences 
Name Sequence Ref. 
CSD-lacF GCTACCATTACCAGTTGGTCTGGTGTC [204] 
CSD-neoF GGGATCTCATGCTGGAGTTCTTCG [204] 
CSD-loxF GAGATGGCGCAACGCAATTAATG [204] 
CSD-Cd47-R TAATTCAGCAGTCCTGATCCCACCC [204] 
CSD-Cd47-ttR CTGTCTCTGTGCTCTCTGGCTAAGG [204] 
CSD-Cd47-F TCTACACTAAACTCAGCTGGCCTGG [204] 
FLP-F (oIMR1348) CACTGATATTGTAAGTAGTTTGC [205] 
FLP-R (oIMR1349) CTAGTGCGAAGTAGTGATCAGG [205] 
neoF Proprietary N/A 
neoR Proprietary N/A 
 
 
Table 3. Primer pairs. 
Allele “Genotype” Forward Primer Reverse Primer Size (bp) Ref. 
tm1a, tm1c Floxed CSD-loxF CSD-Cd47-R 312 [204] 
tm1a PreCre CSD-neoF CSD-Cd47-ttR 603 [204] 
tm1b PostCre CSD-lacF CSD-Cd47-R 610 [204] 
Cd47 (wt) Wild type CD47  CSD-Cd47-F CSD-Cd47-ttR 445 [204] 
tm1c PostFlp CSD-Cd47-F CSD-Cd47-ttR 658 [204] 
tm1d PostFlp&Cre CSD-Cd47-F CSD-Cd47-R 660 [204] 
Flp Flp-expressing FLP-F (oIMR1348) FLP-R (oIMR1349) 725 [205] 
tm1a, Flp neo-expressing neoF neoR 280 N/A 
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Table 4. Cycling parameters for Flp genotyping. 
Step Temp (oC) Time (s) Cycling/Ramp parameters 
1 94 120  
2 94 20 Repeat: Steps 2-4 for 10 cycles. 
Ramp: Decrease temperature in Step 3 1.5 oC each cycle 3 65 15 
4 68 10 
5 94 15 Repeat: Steps 5-7 for 28 cycles.   
Ramp: None 6 50 15 
7 72 10 
8 72 120  
9 4 Hold  
 
Table 5. Cycling parameters for tm1a genotyping. 
Step Temp (oC) Time (s) Cycling/Ramp parameters 
1 94 30  
2 94 15 Repeat: Steps 2-4 for 10 cycles. 
Ramp: Decrease temperature in Step 3 1.0 oC each cycle 3 65 30 
4 72 40 
5 94 15 Repeat: Steps 5-7 for 30 cycles.   
Ramp: None 6 55 30 
7 72  40 
8 72 300  
9 4 Hold  
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4.5.3 Results 
The first tm1a+/- x  tm1a+/- breeding pairs were set up in May 2015. The following is a summary 
of our results at each generation.  These results are visualized in Figure 10. 
4.5.3.1 Founder Generation (Generation Zero): Generation 1: tm1a+/- x  tm1a+/- 
The Jackson Laboratory obtained cryopreserved tm1a+ sperm from our collaborator Dr. 
William Frazier at Washington University. This sperm was used for in vitro fertilization of wild 
type (C57BL6J) oocytes.  These heterozygote (tm1a+/-) embryos were then implanted into wild-
type C57BL6J females (Jackson Labs, Statement of Work Q015966).  Four mice (two male, two 
female) were selected from this litter and became the founding members of our tm1a colony 
(Generation Zero in Figure 10). The founding members of our colony and their progeny were 
genotyped in-house as described in documents provided by KOMP, and representative results are 
shown in Figure 10b. Lung tissue was isolated from tm1a-/-, tm1a+/-, and tm1a+/- progeny, and 
protein immunoblot demonstrated that these mice phenocopy WT, CD47 heterozygote, and 
CD47 null mice respectively (in terms of their expression of CD47) (Figure 10c). 
4.5.3.2 Generation 1: tm1a+/- x  tm1a+/- 
Per [206], Generation 1 consisted of breeding pairs of heterozygote siblings (sibling 
intercross).  Once again, these mice produced a population of tm1a-/-, tm1a+/-, and tm1a+/- mice, 
which were genotyped as above. Heterozygotes were saved for future breeding. (The decision to 
use heterozygote mice rather than homozygote mice was made based on consultation with a 
colleague who was familiar with the technology and found greater success when breeding 
heterozygote mice). 
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Figure 10. Breeding strategy and results.  (a) Breeding strategy.  (b, c) Representative genotyping (b) and 
phenotyping (c) results from generations zero, 1, and 2.  (b) In-house genotyping results using samples from 
generation zero. Heterozygotes in lanes 2, 3, 4 were saved for future breeding. Amplicon sizes are reported at left, in 
basepairs. (c) Protein sizes are reported at left, in kilodaltons.  (d, e, f). Representative genotyping results from 
generations 3 (d), 4 (e) and 5 (f).  An asterisk (*) indicates mice which were saved for future breeding.  Masses are 
reported in base-pairs. 
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4.5.3.3 Generation 2: tm1a+/- x Flp+/+ 
Generation 2 breeding pairs were prepared by mating tm1a heterozygotes (tm1a+/-) with 
Flp deleter mice purchased from the Jackson Laboratory (stock number 009086). These mice 
were genotyped for tm1a, tm1c, and Flp. All progeny were expected to express Flp (and were 
found to do so), having inherited one allele from the Flp expressing parent. A subset of progeny 
experienced Flp-FRT recombination which converted the tm1a allele to tm1c.   
Curiously, we observed that all tm1c+/- Flp+/- mice also appeared to express tm1a as well 
(Figure 10d, lanes 2 and 3). This seemed to suggest either (1) incomplete conversion of the tm1a 
allele to the tm1c allele, yielding tm1c+/- tm1a+/- mosaics or (2) nonspecific binding of the tm1c 
primer pair, yielding a “false positive” tm1c band.   
We hypothesized that the presence or absence of neo would allow us to discriminate tm1a 
“true positives” from “false positives,” since that the tm1a allele contains a neo sequence (and 
the tm1c allele does not). However, we discovered that the Flp allele contains a neo sequence as 
well, and therefore all Generation 2 progeny were expected to be neo-positive. With this finding, 
it was clear that we would not be able to use neo to determine whether we had generated (1) 
tm1c+/- tm1a+/- mosaics or (2) tm1c+/- mice with a “false positive” tm1a signal at this point.   
We elected to wait another generation to resolve this question. We set up Generation 3 
breeding pairs as originally planned: the tm1c+/- Flp+/- mice (which unexpectedly expressed 
tm1a) would be crossed with wild-type mice. We were aware of the possibility that our tm1c+/- 
mice were in fact mosaics (tm1a+/- tm1c+/-).  However, given that tm1c and tm1a alleles reside at 
the same locus, we reasoned that zygotes from mosaic mice would contain either one allele or 
the other, but not both. All future generations of mice were therefore genotyped for neo in 
addition to tm1a, tm1c, and Flp.   
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4.5.3.4 Generation 3: (tm1c+/- Flp+/-) x C57BL6J 
Our tm1c+/- Flp+/- mice were crossed with wild-type mice in order to yield a 
subpopulation of tm1c heterozygotes which did not express Flp (e.g., tm1c+/- Flp-/-).  This step is 
necessary to prevent unexpected genomic recombination due to cryptic FRT sites which may be 
present in the mouse genome [207].   
These mice were genotyped for tm1a, tm1c, Flp, and neo.  A mouse carrying a tm1a 
allele or Flp allele should always carry a neo sequence, due to the way these synthetic alleles are 
constructed.  The absence of a neo sequence would tell us definitively whether or not a particular 
mouse was expressing tm1a or Flp.  
We observed a subpopulaton of mice which were Flp-negative and neo-negative, but 
apparently positive for both tm1c and tm1a (Figure 10e, lane 2). Given that the neo sequence is 
included in the tm1a allele, we could safely conclude that any mice which expressed a tm1a 
signal but no neo signal represented a false positive. Mice which were negative for neo were 
therefore assumed to be negative for Flp and tm1a as well. We would continue to assay for all 
four genes (tm1a, tm1c, Flp, and neo). Mice which were heterozygous for tm1c but were 
negative for neo (tm1c+/- neo(-)) were kept for future breeding.  
4.5.3.5 Generation 4: (tm1c+/- neo(-)) x (tm1c+/- neo(-)) 
In the final generation of breeding, mice which were heterozygous for tm1c but negative 
for neo were bred together to generate a subpopulation of tm1c+/+ neo(-) mice (Figure 10f).  The 
first tm1c+/+ neo(-) mouse was born on June 3, 2016 and was discovered in the June 21, 2016. 
Mice which are homozygous for tm1c can be crossed with Cre expressing mice to generate 
progeny which are homozygous for the tm1d allele. These mice should be complete CD47 
knockouts, and should phenocopy the original CD47 null.  
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4.5.4 Ongoing Work 
The first tm1c+/+ (floxed CD47 mouse) breeding pair has been set up in our colony.  Progeny of 
this pairing will be crossed with global Cre mice in order to generate global CD47 knockouts 
(tm1d+/+).  tm1a+/+ and eventually tm1d+/+ mice, both of which should be CD47 knockouts, will 
undergo kidney ischemia reperfusion injury to demonstrate that they phenocopy the resistance to 
injury that our lab has demonstrated in the CD47 null mouse [103].  
4.5.5 Conclusions 
This chapter has provided a brief review of the literature on TSP1, CD47, and TSP1-CD47 
signaling.  It has summarized the beneficial effects of CD47 blockade which provide a rationale 
for my dissertation project.  It also describes the development of a floxed CD47 mouse line 
which will be used to establish a unique colony here at the University of Pittsburgh for future 
studies examine the role on CD47 signaling in specific cell types in an in situ environment.   
The floxed CD47 mouse will be bred with Cre mice to generate a global knockout.  
Future studies will establish that the floxed mouse phenocopies the wild-type mice (and the Cre 
mouse phenocopies the CD47 null).   
The specific role of TSP1-CD47 signaling in the airway is unknown. Preliminary data 
suggested that differences in the proportions of various cell population within the airway 
epithelium. The next chapter will therefore examine the global CD47 null phenotype in the 
tracheal epithelium.  
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5.0  QUANTIFICATION OF AIRWAY BASAL CELL POPULATIONS USING 
AUTOMATED IMAGE ANALYSIS 
CD47 null tissues show improved healing capacity and survival under stress relative to wild-type 
tissues.  This was first demonstrated in studies examining full-thickness skin grafts [106, 107] 
and has been substantiated using ischemia-reperfusion in multiple organ systems [99, 101, 102, 
208] and radiation models of injury [108-110].  Of note the study of skin graft healing among 
wild type and null mice also found that CD47 null skin grafts healed better on wounds in wild 
type mice than wild type grafts, calling into question the so-called “don’t eat me” signal 
presumed to be mediated by macrophage SIRP-α-mediated phagocytosis of cell not expressing 
CD47. The superior survival of CD47 null tissues has been attributed to the effects of 
thrombospondin-1 (TSP1)-CD47 signaling on the vasculature [181, 186]. TSP1 is secreted under 
conditions of stress, and its ligation of CD47 on endothelial cells redundantly inhibits nitric 
oxide signaling through multiple mechanisms. In doing so, CD47 reduces vasodilation and limits 
angiogenesis. Thus, TSP1-CD47 signaling inhibits tissue perfusion over short- and long- time 
scales, and has a deleterious on tissue survival after injury.   
There is increasing evidence that the TSP1-CD47 signaling axis has effects on tissue 
survival which are independent of its known effects on nitric oxide and the vascular system.  
TSP1 ligation of CD47 has been observed to induce apoptosis in hematopoetic cells through a 
caspase independent mechanism [209-211].  Perhaps more interestingly, TSP1 ligation of CD47 
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has been observed to reduce intracellular levels of multiple key transcription factors associated 
with self-renewal, such as c-Myc, Sox2, Oct3/4 and Klf4 (abbreviated OSKM) [103, 187].   
The overarching aim of my dissertation project is to prepare a functional tissue-
engineered trachea using a decellularized graft. Given the known effects of TSP1-CD47 
signaling on tissue survival, I hypothesize that this signaling axis negatively affects the 
physiology of an engineered graft in a number of ways. It may lead to (1) reduced vascular 
density and perfusion, (2) decreased protein and genomic markers of self-renewal within seeded 
or migrating cells, and (3) decreased numbers of self-renewing progenitor cells within the 
epithelial and stromal tissues.   
Within the tracheal epithelium, keratin 5-expressing basal cells are widely considered the 
progenitor cell population [7, 21-25]. In various injury models, basal cells differentiate into the 
various mature cell populations of the airway, including ciliated and club secretory cells. Basal 
cell self-renewal is driven by the transcription factors p63 and Sox2. Since Sox2 is to suppressed 
by activated CD47 [103, 187], I hypothesized that elimination of the CD47 signaling pathway 
will lead to increased numbers of proliferating basal cells.  This hypothesis was informed by 
preliminary histological stains which seem to indicate increased keratin 14 levels within the 
CD47 null tracheal epithelium at baseline.   
5.1 TECHNICAL RATIONALE 
In previous studies [1], I have quantified the various cell populations within the airway 
epithelium by hand-counting cell nuclei associated with a particular marker. This method is 
tedious and subject to observer bias. Further, it was possible that the cellular distribution of the 
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trachea could be dependent on tissue geometry and orientation of tissue sections.  In light of 
these concerns, a method was developed in order to quantify the cell populations of the airway 
epithelium. Isolation of epithelial cells before staining eliminates tissue geometry as a 
confounding variable, and digital image analysis allows observer-independent quantification.  
This method can be used to fully quantify the various basal cell types in the airway epithelium.  
5.2 METHODS 
5.2.1 Tracheal Harvest and Digestion 
Primary murine tracheal epithelial cells (abbreviated MTECs) were isolated for quantification as 
described [212].  Briefly, tracheas were explanted from three wild-type (WT) and six CD47 null 
mice of a C57BL6 genetic lineage, all 12 weeks of age. Tracheas were further dissected in 
presence of Ham’s F-12 supplemented with 1% penicillin-streptomycin (hereafter Ham’s F-
12/1%PS) to remove connective tissue, and were cut along the longitudinal axis to expose the 
lumen. Each dissected and opened trachea was placed in a 15 ml conical tube containing 0.15% 
Pronase from Streptomyces griesus (Roche Applied Science 10165921001) in Ham’s F-
12/1%PS.  These tubes were placed on a rocker at 4 oC for 18 hours to loosen epithelial cells 
attachment to the extracellular matrix. Subsequently, FBS was added to each tube to bring the 
final serum concentration to 10% and halt the digestion.   
Epithelial cells were released from the tissue by mechanical agitation. Each tube 
containing one digested trachea was rapidly inverted 20 times in order to separate cells from the 
extracellular matrix.  After agitation, each trachea was lifted into a second tube containing Ham’s 
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F-12/1%PS/10% FBS, which was itself inverted 20 times. This process was repeated until the 
tracheas had passed through four tubes, and the remnant tracheal tissue was discarded.  
Supernatants were pooled in the final tube and centrifuged (500 x g, 5 minutes, 4 oC).   
Each pellet was resuspended in MTEC BASIC media (as described in literature [212]: 
DMEM/F12 supplemented with 15 mM HEPES, 1% Penicillin-Streptomycin, 4.0 mM L-
glutamine, 7.5% sodium bicarbonate) further supplemented with 10% fetal bovine serum.  The 
resuspended cells were incubated in a tissue culture dish at 37 oC to remove fibroblasts via 
differential adherence to plastic.  After four hours, the supernatant was removed from each dish 
and the adherent fibroblasts were discarded.  The supernatant was centrifuged once again (500 x 
g, 5 mins, 4 oC) to collect mouse tracheal epithelial cells.   
Each pellet was resuspended in 200 microliters Ham’s F-12/1%PS/10% FBS and cells 
were counted using a hemacytometer.  Cells from each animal were spun onto two slides at 1000 
RPM for 15 minutes and stored at -20 oC until staining.  
5.2.2 Keratin-5/Keratin-14 Cytospin Staining 
The following was adapted from a collaborator’s protocol (T. Gilbert):  
Cytospun slides were incubated in PBS supplemented with 0.5% Triton X-100 for 30 
minutes at room temperature in order to permeabilize cells. Blocking was performed with 
PBS/0.5% Triton X-100/5% bovine serum albumin for 45 minutes at room temperature. Slides 
were subsequently washed three times with PBS. The following antibodies were diluted in 
blocking buffer (PBS/0.5%Triton X-100/5% BSA) and were applied in sequence, with 
intervening PBS washes: (1) Rabbit anti-keratin 14 (Covance PRB-155P) (1:500) for 90 minutes 
at room temperature; (2) AlexaFluor-488 conjugated donkey anti-rabbit IgG (Life Technologies 
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A21206) (1:500) for 90 minutes at room temperature; (3) anti-Rabbit blocking antibody fragment 
(Jackson ImmunoResearch 111-007-003), overnight, at 4 oC; (4) Rabbit anti-keratin 5 (Covance 
PRB-160P) (1:1000), for 90 minutes at room temperature; (5) AlexaFluor-594 conjugated 
donkey anti-rabbit (Life Technologies A21207) (1:500), for 90 minutes at room temperature.  
After three washes each in blocking buffer and PBS, all slides were mounted with a DAPI-
containing mounting medium (Vector Laboratories H-1200) and imaged within 48 hours.   
5.2.3 Imaging and Quantification 
Each cytospun slide was imaged repeatedly (at between six and ten non-overlapping locations).  
At each location, three images were captured corresponding to each of the three stains: (1) 
DAPI-stained nuclei, (2) AlexaFluor 594-stained keratin 5, and (3) AlexaFluor 488-labeled 
keratin 14.  A novel MATLAB script, titled “CytoAnalysis”, was developed to correlate AF594- 
and AF488-labeled objects to DAPI-stained nuclei in order to determine the fluorescence 
intensity of each imaged cell.  This program is summarized briefly below, but is reproduced in 
full in the Appendix (page 124). 
The following lines of MATLAB code from the program runcytoanaysis.m 
summarize the core of the segmentation technique.  This code has been greatly abbreviated and 
slightly modified for clarity.   
 ... 
% load the image file into memory 
gray = imread(filename); 
% create a binary mask 
mask = im2bw(gray, graythresh(gray)); 
% identify objects, and calculate properties 
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imstats = regionprops(mask, gray, {'Area', 'PixelIdxList', 
'MeanIntensity'});  
... 
Each captured image is loaded into memory as a grayscale image, gray.  The MATLAB 
graythresh function determines a pixel intensity threshold which discriminates brighter, 
positively-stained pixels from dark background pixels.  A call to the MATLAB function im2bw 
converts the original grayscale image into a binary image mask, in which pixels with intensity 
values above this calculated threshold are white and pixels below this threshold are black (Figure 
11a).  The mask was used to generate a list of discrete “objects” and determine their properties.  
An area (Area) and mean pixel intensity (MeanIntensity) was calculated for each object, and 
a list of all pixels within the object’s borders was generated (PixelIdxList).    Objects smaller 
or larger than user-defined limits were discarded from further analysis. 
To identify individual cells, DAPI was selected as a universal marker.  Within each set of 
three images, objects in the keratin 5 image were associated with objects in the corresponding 
DAPI image on the basis of shared pixels. The same process was repeated for objects in the 
green (keratin 14) channel.  In this way, the degree of keratin 5 or keratin 14 fluorescence (if 
any) could be quantified for each DAPI-stained object, and a histogram could be prepared 
showing the distribution of fluorescence intensities for all the cells within a given set.  These 
results were plotted as shown (Figure 11b-d). 
5.2.4 Cell Cataloguing 
DAPI-labeled objects were sorted into four groups based on the degree of fluorescence intensity 
relative to a user-defined threshold: (1) K5-low/K14-low “double negative” cells (2), K5-
high/K14-low cells, (3) K5-high/K14-high “double positive” cells and (4) K5-low/K14-high 
 87 
cells.  The fraction of the total number of cells within each of the four groups was calculated 
(Figure 11e).   
 
Figure 11. CytoAnalysis automatically counts and characterizes fluorescent objects.   Above is an example of 
data output from a single animal. (a) Demonstration of the “masking” technique by which the program identifies 
pixels corresponding to individual objects. Objects matching the proper inclusion criteria are highlighted in pink (b-
d) Histograms demonstrate the distribution of fluorescence intensity of all objects within a given set of images for a 
particular slide. The dotted line marks the boundary between cells determined to have “high” and “low” expression 
of a particular marker.  (e) Once the program has determined the keratin 5 and keratin 14 fluorescence intensity for 
each cell, a scatter diagram can be prepared which shows four distinct groups of objects. On this particular slide, a 
higher than normal number of cells showed a keratin-5 signal above the defined threshold.   
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5.3 RESULTS 
5.3.1 CytoAnalysis identifies cells and quantifies fluorescence intensity 
Cells were isolated from three wild type C57BL6 mice and six CD47 null male mice, 12 weeks 
of age, of the same genetic background. Two cytospin slides were prepared for each animal. One 
of the two was triple-stained for keratin 5, keratin 14, and DAPI as described above. Images 
were captured from between six and 10 non-overlapping locations in each slide.  The total 
number of cells analyzed for each slide averaged n = 445.8±176.0 cells.   
5.3.2 CD47 null and wild-type tracheal tissues have equal distributions of basal cell 
populations 
Keratin-5 is generally considered a universal airway basal cell marker, as it is expressed both in 
quiescent and proliferative states [24]. In the wild-type and CD47 null mice, keratin-5-expressing 
basal cells comprised 30.0±2.54% and 30.1±3.9% of the total number of isolated cells, 
respectively. These numbers match literature reports, which have indicated that keratin 5 
expressing basal cells represent about 30% of the epithelial population within the trachea [24, 
25]. 
Within this population, a subset of dual-positive (that is, keratin 5-positive and keratin 
14-positive) cells represent a proliferative population. Dual expressing cells comprised 
10.4±4.46% of all cells isolated from three wild type mice, and 8.08±2.75% of cells isolated 
from six CD47 null mice.  A full breakdown of basal cell subpopulations is given in Table 6 and 
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is summarized in Figure 12.  No statistically significant differences were observed in basal cell 
populations.   
Table 6. Mean distribution of basal cell populations within the tracheal epithelium. 
 WT (n = 3)  CD47 null (n = 6) 
 mean ± sd  mean ± sd 
Other 68.9 ± 3.0  69.2 ± 4.1 
K5 only 19.5 ± 2.1  22.0 ± 2.0 
K5 K14 dual 10.4 ± 4.5  8.1 ± 2.8 
K14 only 1.1 ± 9.8  7.0 ± 0.5 
K5 total 30.0 ± 2.5  30.1 ± 3.9 
K14 total 11.6 ± 4.6  8.8 ± 3.0 
Count  399.3 ± 178.9  469.0 ± 186.6 
 
 
 
Figure 12.  Distribution of basal cell populations within the tracheal epithelium. 
  No statistically significant differences were observed. 
 
 
 
 90 
5.4 DISCUSSION 
5.4.1 Limitations 
There were a number of limitations to the method employed in this study.  First, while it is a 
simple to compare relative fluorescence intensity between objects on a particular slide, 
fluorescence intensity could not be easily compared between slides. This is due to the fact that a 
given object’s intensity is not solely a function of protein expression; rather it is also dependent 
on (1) antibody affinity, (2) incubation times, (3) exposure time at time of imaging, and (4) the 
length of the time interval between staining and imaging. Steps were taken to control these 
variables, but the exact relationship between fluorescence intensity and protein expression is not 
clear.  Thus, while comparisons of fluorescence intensity could be made between objects within 
a particular slide, such comparisons may not be appropriate between objects on different slides. 
Despite this limitation, objects could be sorted into relative “high” and “low” intensity groups. 
Therefore, conclusions could be drawn based the proportion of cells within these categories. 
Another limitation is that the process of cell separation and harvest from the trachea may itself 
alter the relative expression levels of genes as compared to the in vivo setting.  
5.4.2 Conclusion 
The CD47 null genotype, though associated with elevated markers of self-renewal, does not 
appear to be associated with elevated numbers of keratin 5-expressing (or keratin 5/keratin 14 
dual expressing) basal cells within the tracheal epithelium. This finding stands in contradiction to 
preliminary data which seemed to indicate greater keratin-14 expression in CD47 null mice 
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trachea airways, suggesting gene expression levels in these cells is context dependent. There may 
be any number of reasons for this. First, TSP1 and CD47 are both upregulated in stressed 
conditions including with cell isolation and culture, and TSP1 in particular is expressed at very 
low levels at baseline. Yet it is possible that there is not enough TSP1 in the native tracheal 
epithelium at rest in order to cause significant differences in the physiology of the airway 
epithelial cell population.   
Second, while basal cells are considered the progenitor cell population of the airway 
epithelium, it has been suggested that not all basal cells are equally “multipotent” [23].  In light 
of this, keratins 5 and 14 may not be the best markers in order to quantify differences in 
progenitor cell number within CD47 null tissues, as they are universal markers for the entire 
basal cell pool. The transcription factors p63 and Sox2 may be more appropriate: both of these 
are expressed by self-renewing basal cells [13, 14], and as we and others have shown Sox2 in 
particular is regulated by TSP1-CD47 signaling [103, 187].  However, the low quantities of these 
proteins (relative to a cytoskeletal molecule like keratin) makes them less-than-ideal targets for 
this technique.   
The technique described in this study is a straightforward method by which airway 
epithelial cell populations can be analyzed, while eliminating observer bias and the potential 
effects of tissue geometry. Data gathered using the technique described in this study suggests 
that approximately 30% of the cells within a wild-type C57BL6 mouse trachea are basal cells.  
The fact that this proportion matches what has been previously reported in the literature [24, 25] 
lends credence to the idea that this is a reliable and scientifically valid method to quantify cell 
populations within the airway epithelium.   
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6.0  MALADAPTIVE TSP1-CD47 SIGNALING LIMITS AIRWAY RESTORATION 
AND HEALING OF DECELLULARIZED TRACHEAL TRANSPLANTS 
(Portions of this chapter will be used in an upcoming manuscript: Kutten, J.C., et al., 
Maladaptive TSP1-CD47 Signaling Limits Airway Restoration and Healing of Decellularized 
Tracheal Transplants. In preparation.) 
The trachea is a highly specialized structure composed of unique epithelial cellular types 
including basal cells, club cells, and ciliated cells. The stromal cell populations include 
chondrocytes arranged in a series of C-rings bridged by fibrous tissue and smooth muscle. The 
result is a structure that is both rigid enough to provide a patent and stable airway and yet can 
accommodate a wide range of motion. Unlike many other composite tissues in the body that are 
amenable to reconstruction with surrogate tissue types, there is nothing that can be enlisted to 
mimic the proximal airways. Thus, tracheal deficiency due to congenital causes [42] or 
malignancy [44, 45] represents is a life threatening problem without an effective surgical 
solution. Current approaches to address this include slide tracheoplasty [38, 39, 41], long-term 
stenting, intermittent dilation, tracheostomy and in a rare instances tracheal transplantation [51, 
53]. Regardless of the approach the complication rates remain very high [56] and have provided 
inspiration for the development of a functional bioengineered tracheal transplant. Common to 
these efforts has been to begin with either a decellularized tracheal allograft or a synthetic 
polymer/nanofiber scaffold and then seed the three dimensional scaffold with cells and growth 
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factors [49, 50]. Some published reports have also indicated that regional pedicle soft tissue 
flaps, most commonly derived from the greater omentum, [19] are then employed to envelope 
the transplant and  provide angiogenic stimuli and to render a sterile barrier between the chest 
cavity and the transplant. The clinical reports of bioengineered tracheal transplantation, although 
receiving significant media attention, remain hampered by very poor outcomes [98] including 
delayed healing and non-healing, transplant collapse and suffocation, infection, fistula formation 
between the trachea and other chest organs, respiratory ventilator dependency and in many cases 
death. However, the molecular and cellular processes controlling the survival and healing of the 
bioengineered tracheal transplants are incompletely defined. 
Thrombospondin-1 (TSP1) is a matricellular protein upregulated with injury [138]. As a 
secreted protein it can alter cell activity through engagement of cell surface receptors. One such 
high affinity interaction occurs with CD47 [111, 112]. In this capacity TSP1 limits multiple 
restorative pathways including growth factors such as vascular endothelial growth factor (VEGF) 
and the biogas nitric oxide [181, 186]. Animals lacking CD47 show accelerated healing after 
skin graft transplantation [106, 107]. Conversely, therapeutically blocking the TSP1-CD47 
interaction significantly improves the healing of hypoxic and ischemic tissues and organs [99, 
106, 138, 213-215], and also limits radiation-induced cell death [108-110].  Perhaps more 
significantly, we and colleagues reported that key transcription factors known to control 
pluripotency and self-renewal were inhibited by TSP1-CD47 signaling [103, 187]. The specific 
role of TSP1 and CD47 in the trachea and proximal airway is unknown, but reports suggest that 
TSP1 ligation of CD47 may have a deleterious effect on airway healing. In asthma-induced 
inflammation TSP1 expression is increased [216], while TSP1 null mice show greater levels of 
club cell repopulation after chemical injury [139]. These results indicate that TSP1 is increased 
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in airway inflammation and impedes healing, and form a further basis for my hypothesis that 
maladaptive TSP1-CD47 signaling impedes airway healing and limits restoration of orthotopic 
decellularized tracheal transplants.   
To test this hypothesis, we developed a unique murine syngeneic orthotopic tracheal 
transplant model and assessed healing in vivo and in vitro analyzed the restorative potential of 
tracheal epithelial cells. TSP1 and CD47 protein expression was essentially undetectable in 
healthy airways and tracheas but both were increased following short-term hypoxia. In vitro, 
human airway epithelial cell (HAEC) proliferation and response to wounding was inhibited by 
exogenous TSP1 and these responses were mitigated by treatment with a CD47 blocking 
antibody. CD47 null tracheal and airway epithelial cells (TECs) displayed increased proliferation 
and migration compared to wild type cells providing genetic confirmation of the signaling axis. 
Multiple key self-renewal transcription factors were increased in at the levels of message and 
protein in intact CD47 null airways and in CD47 null TECs compared to wild type airways and 
cells including octomer-binding transcription factor 4 (Oct4), sex determining region Y-box 2 
(Sox2), Kruppel-like factor 4 (Klf4) and cellular homolog of the v-myc avian myelocytomatosis 
viral oncogene homolog (c-Myc), (abbreviated OSKM). Furthermore, CD47 null airways 
showed enhanced healing following chemical injury compared to wild type animals. Finally, 
decellularized tracheal transplants were more rapidly resurfaced when transplanted into 
orthotopic defects in CD47 null recipients versus similar decellularized tracheal transplants in 
wild type recipients. Together, these data indicate that maladaptive upregulation of the TSP1-
CD47 axis in airway injury limits epithelial cell self-renewal and repair to suppresses restoration 
following both chemical injury and tracheal transplantation.  
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6.1 MATERIALS AND METHODS 
6.1.1 Animal Studies 
All studies were performed under protocols approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee in accordance with NIH guidelines. Male C57BL6 
wild-type (WT, CD47+/+) and CD47 null mice (B6.129S7-Cd47tm1Fpl/J), catalogue numbers 00664 
and 003173 respectively, were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). 
6.1.2 Human Airway Epithelial Cell Isolation 
Human airway epithelial cells (HAECs) were isolated employing a well-established technique at 
the University of Pittsburgh and under an approved IRB (protocol number: IRB970946). Briefly, 
approximately three centimeters of the proximal airway were cut from fresh human lungs and 
trimmed of excess parenchyma. Each section was cut open lengthwise and placed in sterile, cold 
EMEM/HEPES (Sigma M2645) with added sodium bicarbonate (Sigma S6297) solution (pH = 
7.4), hereafter referred to as EMEM/HEPES media. The samples in media were placed on a 
rocker at 4o C overnight. After aspirating the media, the samples were trimmed a second time, 
rinsed in EMEM/HEPES media, and placed in cold protease solution (Sigma P5147, 1 mg/ml in 
EMEM/HEPES media) for 36 to 48 hours. 10X collagen coating solution was prepared by 
combining 5 mg collagen from human placenta (Sigma C7521) into 50 ml of 0.035 M acetic acid 
in water.  This 10X stock was incubated at 4 oC overnight and filtered. To prepare a 1X working 
stock, 10X collagen coating solution was diluted 1:10 in 0.01M Na2CO3. Appropriate volumes of 
1X collagen solution were pipetted into tissue culture flasks, dishes, and plates that were then 
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allowed to incubate for at least 30 minutes at 37 oC. After incubation the solution was removed 
and an appropriate number of cells were seeded for each application. HAECs were supported 
with BronchiaLife Complete Media (LifeLine Cell Technology, Frederick, MD) that was 
replenished every other day and were passaged at 80% confluence onto new collagen coated 
plates or flasks.   
6.1.3 Human Airway Epithelial Cell Culture 
Human airway samples were briefly digested with protease. The protease was collected in a 50 
ml conical tube and sufficient fetal bovine serum (FBS) was added to bring the final 
concentration to 5% and halt digestion. Each section of tissue was placed into a sterile tissue 
culture dish and the luminal surface was scraped with a sterile scalpel to liberate cells. The tissue 
culture dish was washed in cold EMEM/HEPES to collect the cells. The cell-containing media 
was diluted in 200 ml of EMEM/HEPES and split into four conical tubes. All tubes were 
centrifuged (200 x g, 4 oC, 5 min). The supernatant in each tube was aspirated and replaced with 
20 ml Accutase (Sigma 6964). The cells were incubated in Accuatase on a rocker at 4o C for 10 
min, and 1 mL FBS was added to stop the digestion. The cells were centrifuged a second time 
and were suspended in sterile, complete BronchaLife Complete Media with 1% penicillin-
streptomycin. After counting, approximately 2 x 106 cells were seeded into collagen-coated T75 
flasks.   
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6.1.4 Cell Proliferation Assays 
MTS proliferation assays (Promega CellTiter 96 AQueous One Cell Proliferation Assays G3580) 
were performed according to the manufacturer’s instructions. Cells were passaged and 2500 cells 
in 100 ul of media were seeded into wells of collagen-coated 96-well plates. The cells were 
allowed to adhere overnight and the media was replaced with 200 ul of media containing the 
indicated treatments. Combinatorial groups of the following were applied as described in the 
results section: mouse IgG1 anti-human CD47 (clone B6H12, Santa Cruz sc-12730, 1 ug/ml), 
normal mouse IgG1 (Santa Cruz sc-3877, 1 ug/ml), human thrombospondin-1 (TSP1, Athens 
Research 16-20-201319, at 2.2 nM, 5.0 nM, and 10 nM).  In groups where blocking antibodies 
were combined with TSP1, cells were allowed to incubate in media containing the antibody 
alone for thirty minutes before it was replaced with media containing both the antibody and 
TSP1. After 72 hours of proliferation under each treatment condition 100 ul of media was 
removed and 20 ul MTS Reagent (Promega) was added to each well. The wells were allowed to 
incubate for 2-3 hours before absorbance was read at 490 nm on a spectrophotometer.   
6.1.5 Cell Hypoxia 
1 x 105 HAECs were seeded onto collagen coated plates as above and grown to 80% confluence. 
On the day of treatment, the media was changed and cells containing flasks were placed in a 
normoxic incubator or a hypoxic incubator (FiO2 1%) for two or twelve hours. Afterward the 
media was collected, and plates were washed with PBS before cell collection and protein 
isolation.   
 98 
6.1.6 Scratch Wound Healing Assays 
Cells were seeded onto collagen-coated plates and grown to 80% confluence. At t = 0 hours, 
media was aspirated from each well and a single scratch was drawn across the surface using a 
p10 pipette. Each well was gently washed twice with PBS in order to remove debris before 
adding BronchiaLife Complete media. Three images were taken of each well at t = 0, 2, 6 and 10 
h. There regions within each well were photographed at each time point. Care was taken to 
ensure that the same locations were photographed between time points. Images were de-
identified during quantification in order to control for observer bias. For each image, ImageJ was 
used to identify contiguous regions containing no cells (or non-confluent cells). If multiple such 
areas were identified in a single image, the region with the largest area was used. The mean area 
of all three images from a given well at a given time point was taken to be representative of the 
area of the scratch.  Wound areas from three scratches in three separate wells were averaged, and 
normalized to the wound area at time t = 0, in order to calculate “percent wound closure.” 
 
6.1.7 Human Airway Epithelial Cell Organoid Cultures 
The sphere (organoid) culture protocol was adapted from the literature [24, 29, 217]. Briefly, 
human airway epithelial cells in BronchiaLife proliferation media were counted and resuspended 
in UNC/USG media [218] at a concentration of 2x105 cells/ml. Where applicable, differentiation 
media contained the indicated treatments (2.0 μg/ml B6H12 and/or 20 nM TSP1).  In cases 
where the two treatments where combined, the cells were incubated first in B6H12 for at least 30 
minutes before adding TSP1. The mixture of cells in differentiation media was combined 1:1 
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with growth-factor reduced Matrigel (Corning 356230) to prepare a final cell- and treatment-
loaded gel solution (1x105 cells/ml, ±1.0 μg/ml, ± 10 nM TSP1). 100 μl of the final gel solution 
were pipetted into the apical chambers of TransWell Clear membrane inserts (Corning 3740) 
placed in 24-well plates. Three wells were prepared for each of the four treatment groups.  Plates 
were maintained at 37 oC to allow the gels to solidify before adding 800 μl of treatment-loaded 
differentiation media into the basolateral chamber of each well. Basolateral media was changed 
every two-to-three days. Four photographs were taken of each well on the day of seeding, plus 
every seven days thereafter.  ImageJ was used to determine the cross-sectional area of objects 
within each photograph. An average cross sectional area was determined for each well, and the 
average cross sectional area was calculated for each treatment. At the final time point, gels were 
gently aspirated, pipetted into TissueTek cassettes, submerged in OCT media, and frozen for 
sectioning. 
6.1.8 Porcine Tracheal Matrix (PTM) Scaffolds 
Decellularization was performed in accordance with previously published protocols [1, 133] with 
some modifications. This process is summarized in Figure 15a.  Briefly, porcine tracheas (kindly 
provided by Dr. Mauricio Rojas, University of Pittsburgh) were frozen overnight at -80 oC.  
Tracheas were then thawed in sterile MilliQ deionized water and exposed to a series of washes in 
freshly prepared 3.0 M NaCl, 3% Triton X-100, and sterile water. Each wash was performed at 
200 RPM on a laboratory rocker for greater than eight hours. This was followed by sanitization 
in a 0.1% peracetic acid/4% ethanol solution in deionized water, followed by washes in sterile 
PBS and water. Once sanitized, the tracheas were cut into square sections (approximately 0.7 cm 
x 0.7 cm) under sterile conditions and stored in PBS + 1% antibiotic-antimycotic until use. PTM 
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scaffolds were held in place using Sigma Cell Crown 24 inserts in 24 well-dishes and were 
soaked in BronchiaLife media before cell seeding. 
6.1.9 Airway Epithelial Cell Adhesion Assay 
1 x 105 HAECs were seeded onto each PTM scaffold in BronchiaLife media. The cells were 
allowed to adhere overnight and the scaffolds were rinsed in PBS. After rinsing, the scaffolds 
were moved to fresh plates and cells were allowed to proliferate for 3 days before further 
analysis.  For histological analysis, intact porcine tracheas, unseeded PTM scaffolds, and seeded 
PTM scaffolds were fixed in 4% paraformaldehyde/PBS for 24 hours before embedding and 
sectioning.  
6.1.10 Western Blot Analysis 
Western Blots were performed using standard protocols. Briefly, complete RIPA buffer was 
prepared from stock RIPA buffer (Cell Signaling 9806S) supplemented with PhosSTOP 
phosphatase inhibitor (Sigma 4906837001) and protease inhibitor (Sigma P8340). Cell-culture 
dishes were washed twice with PBS, frozen overnight, and incubated on ice for at least 45 
minutes in complete RIPA buffer before lysates were collected. Likewise, whole tissues were 
submerged in complete RIPA buffer and were ground with a mortar and pestle over a 45-minute 
period interspersed with incubations on ice. Lysates were centrifuged at 17000 X g and 
supernatants were kept frozen at -80º until analysis. Protein concentration was determined via 
RC DC Protein Assay (BioRad, Berkley, CA). Samples were then run on acrylamide gels (8%) 
and transferred onto nitrocellulose membranes (BioRad). In most cases, samples were prepared 
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under reducing/denaturing conditions, with the exception of samples intended for CD47 protein 
detection (which were prepared under non-reducing/denaturing conditions). The following 
primary antibodies were used at the indicated dilutions in LiCor Odyssey Blocking Buffer: 
Rabbit anti-c-Myc IgG 1:1000 (Abcam ab69987), rabbit anti-Klf4 IgG 1:1000 (Abcam 
ab151733), rabbit anti-Oct4 IgG 1:1000 (Abcam ab18976), rabbit anti-Sox2 1:1000 (Abcam 
ab97959), rabbit anti-ΔNp63 (clone Poly6190, Biolegend 619002), rabbit anti-CC10 1:200 
(clone FL96, Santa Cruz sc-25555), mouse anti-TSP1 IgG1 1:500 (clone A6.1, Abcam ab1823), 
rat anti-mouse CD47 1:500 (clone MIAP301, Santa Cruz sc-12731), mouse anti-human CD47 
1:500 (clone B6H12, Santa Cruz sc-12731).  Rabbit anti-beta actin 1:5000 (Cell Signaling 4967) 
was used as a loading control.   
6.1.11 qPCR analysis 
RNA was isolated from tissues using a RNEasy Mini kit (Qiagen, Netherlands) and the 
manufacturers’ instructions.  cDNA was prepared from total RNA using LAMDA Biotech G206 
kit (St. Louis, MO, USA). Aliquots of cDNA were diluted to 10 ng/μL, and 4.5 μL cDNA was 
combined with 5.0 μL of ROX reaction mixture (Thermo Fisher 11745500) and 0.5 μL of the 
appropriate TaqMan primer (ThermoFisher) to make a reaction mixture of 10.0 μL per well. The 
following TaqMan Gene Expression Assay were employed: Klf4 (Mm00516104_m1), Pou5f1 
(also known as Oct4) (Mm03053917_g1), Sox2 (Mm03053810_s1), Myc (Mm00487804_m1), 
Cd47 (Mm00495005_m1), Thbs1 (also known as TSP1) (Mm01335418_m1), Krt5 
(Mm01305291_g1), Krt14 (Mm00516876_m1), FoxJ1 (Mm01267279_m1), Scgb1a1 (also 
known as CCSP) (Mm00442046_m1), Hprt1 (Mm01545399_m1).  
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qPCR was performed according to the manufacturers’ instructions.  Briefly: each 20X 
assay was combined with appropriate volumes of cDNA and Platinum PCR SuperMix-UDG 
with ROX (Thermo Fisher 11743-500) within each well, and samples were run in triplicate.  
Fold-change was calculated using the ΔΔCT method, with Hprt1 as a housekeeping gene.   
6.1.12 Ex vivo airway angiogenesis assay 
Collagen type I-based gel solution was prepared as we published [184] using these ratios of the 
following reagents: 8.0 mL PureCol (stock: 3 mg collagen/mL, Fisher 50-350-230), 0.8 mL 10x 
M199 media (Sigma M0650), 74 μL L-glutamine (CellGro 25-005-CI), 74 μL 
penicillin/streptomycin (MediaTech MT30-002CIRF), and 1.0 mL of a pre-prepared 11.8 mg/mL 
sodium bicarbonate (Sigma S5761) solution in water. Sodium hydroxide (1.0 M) was added 
drop-wise to the solution to bring it to a pink color. 300 μL of the collagen gel solution was 
deposited into 16 wells of a 24-well plate, and the plate was incubated at 37 oC until the gel 
solution had solidified.  Tracheas were harvested from male 12-14 week old wild-type C57BL6 
and CD47 null mice and cleaned under a dissection microscope. These were then cut into one- 
ring sections using a scalpel. The rings were placed flat in one well of the prepared 24-well plate, 
and covered with an additional 400 μL collagen gel solution. The plates were allowed to incubate 
until the covering gel had solidified, and 400 μL of gowth media was added.  Media was changed 
on the day immediately following gel placement and on every second day thereafter. Images 
were captured of each well on each day.  In each photograph, the well was positioned such that a 
90o arc of the explant ring’s edge was contained in one quadrant of the image. This allowed the 
position of each well to be reproduced daily so that the degree of cell migration could be reliably 
quantified. To quantify cell migration, ImageJ was used to determine the pixel coordinates which 
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defined (1) the boundaries of the explant and (2) the locations of cells within each image. These 
results were exported to a data file, and a MATLAB script was designed to determine the 
shortest distance between each cell and the nearest explant border. Cell counts and mean cell 
migration distance could then be determined from analysis of this data.   
6.1.13 In vivo Chemical Airway Injury  
10- to 12- week old male wild type and CD47 null mice were obtained from the Jackson 
Laboratory or bred within our animal colony.  Airway epithelial cell depletion was performed on 
these mice as previously described. Briefly, naphthalene (Sigma, St. Louis, MO, USA) was 
dissolved in corn oil (Sigma C8267) at a concentration of 0.275 mg/ml.  Mice were weighed and 
then injected with naphthalene-corn oil solution to reach a dose of 275 mg/kg body mass. Mice 
were treated twice daily with subcutaneous 5% dextrose in normal saline for the first three days 
after the procedure. At indicated time points, mice were sacrificed via carbon dioxide exposure 
followed by exsanguination. Tracheas were cut open longitudinally along the trachealis muscle 
and embedded in OCT (TissueTek, Sakura Finetek USA, Torrence CA) for later tissue 
sectioning, and lung tissues were snap frozen for protein isolation.   
6.1.14 Decellularization of Murine Tracheas 
Mouse trachea decellularization was performed as previously published with slight modifications 
[1].  Briefly, fresh mouse tracheas are trimmed of excess tissue, frozen overnight, and thawed in 
MilliQ distilled water. They were then treated with washes of water, 3% Triton X-100, and 3 M 
NaCl while in a pressure chamber which cycles between normal atmospheric pressure and a 
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vacuum. After these washes, the tracheas were sanitized via a 0.1% peracetic acid/4% 
ethanol/water solution and were rinsed thoroughly with water and PBS before being stored in 
PBS supplemented with 1% antibiotic/antimycotic. In all cases, less than 24 hours passed 
between the completion of the final wash and the start of transplant surgery.   
6.1.15 Murine Orthotopic Tracheal Transplantation Model 
We conducted murine orthotopic tracheal transplantations of freshly decellularized tracheas 
obtained from wild type mice as we previously published [1] with minor variation. Briefly, mice 
were anesthetized with 80 mg/kg ketamine and 8 mg/kg xylazine and placed supine on a heating 
pad throughout the surgery. The cervical trachea was exposed via a midline incision. Two 
tracheal rings were dissected from the surrounding connective tissue and were resected, starting 
at four rings below the larynx. Care was taken to protect the recurrent laryngeal nerves 
throughout the procedure. The decellularized tracheal graft was positioned in the defect, and the 
anastomoses were made (first distal, then proximal) with interrupted 10-0 Prolene sutures 
(Ethicon). The skin incision was closed with 7-0 PDS sutures. Mice were monitored under a 
warming lamp until they had fully recovered from anesthesia and were ambulatory. The 
operative time averaged 30 minutes.  
6.1.16 Decellularized Tracheal Transplantation Post-Operative Care 
Mice were housed singly after surgery. Food and water were supplied ad libitum. Subcutaneous 
injections of the following were administered each day following surgery: buprenorphine (0.1 
mg/kg) twice daily for pain relief, and gentamicin (8 mg/kg) once daily for infection prophylaxis.  
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Four days after surgery, mice were euthanized with an intraperitoneal injection of 
ketamine/xylazine and immediate exsanguination. The tracheal transplants were harvested, using 
the Prolene sutures as landmarks, for immediate processing.   
6.1.17 Tissue Histology and Quantification 
Tissue embedding and sectioning was performed by the Research Histology Services at the 
University of Pittsburgh. Multiple images were taken of each slide and the images were 
combined in Adobe PhotoShop CS6 in order to create a photomosaic which spanned the entire 
length of the trachea.  In the naphthalene treated mice, keratin-5/keratin-14 dual staining cells 
could be observed in a patchy distribution along the luminal surface of the airway at the 4- and 7- 
day time points. The lengths of the entire trachea epithelium and the lengths of each dual-
staining patch were measured, and the surface-coverage was calculated.  After four days, mice 
receiving decellularized grafts showed a clear “migratory front” as keratin-5/keratin-14 cells 
migrated along the graft lumen.  Measurement was taken along the epithelium from the far end 
of the native cartilaginous ring immediately adjacent to the anastomosis to the end of the 
migratory front.  This measurement was averaged from up to four sites on a given slide.   
6.1.18 Statistics 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad, La Jolla, CA).  In 
general, data are presented as mean ± one standard deviation (SD) for each group.  Intergroup 
differences were assessed with two-way analysis of variance (ANOVA).  Statistical significance 
was defined as p< 0.05.   
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6.2 RESULTS 
6.2.1 TSP1, via CD47, inhibits HAEC proliferation and growth in multiple in vitro models 
of healing. 
 Proliferation is an essential cell response to injury and necessary for healing. TSP1-CD47 has 
been noted to broadly regulate cellular differentiation and proliferation in response to stress 
HAEC cell cultures treated with exogenous TSP1 over 72 h displayed decreased  proliferation in 
a dose-dependent manner (Figure 13a, on page 107). This inhibitory effect was abrogated by pre-
treatment of cells with a CD47-blocking antibody (clone B6H12, 1.0 μg/ml) (Figure 13b). To 
further assess the role of TSP1 in epithelial healing, confluent HAEC layers were scratched and 
surface coverage was determined at several time points post-injury. Although exogenous TSP1 
treatment (2.2 nM) did not significantly alter cell resurfacing of the scratch under these 
conditions, treatment with the CD47-blocking antibody accelerated wound closure in both the 
presence and absence of exogenous TSP1 (Figure 13c, d).   
Finally, a sphere-forming assay [24, 29, 217], was employed to assess ex vivo the role of 
TSP1 on airway cell differentiation.  Over the course of 20 days airway epithelial cells seeded in 
a 1:1 media:Matrigel mixture proliferated and formed “bronchospheres” which morphologically 
resembled the native airway epithelium (Figure 13e). By 14 days, bronchospheres in wells 
treated with TSP1 were hypoplastic (less developed) relative those in untreated wells. The 
inhibitory effect on bronchosphere size found in TSP1 treated systems was abrogated by 
treatment with the CD47 blocking antibody (clone B6H12) (Figure 13f).  
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Figure 13. TSP1, via CD47, inhibits HAEC proliferation and growth in multiple in vitro models of healing.  
(a) MTS proliferation assay of HAECs, over 72 hours, using a number of TSP1 doses. (b) MTS proliferation assay 
of treated cells (±10 nm TSP1; ± CD47 antibody clone B6H12, 1 µg/ml). Results are the mean ± SD; * indicates p < 
0.05. (c, d) Scratch assay wound closure after t = 10 hours (±10 nm TSP1; ± CD47 antibody clone B6H12, 1 µg/ml).  
Each symbol represents the mean of three measurements in a given experiment; n = 3 experiments. * indicates p < 
0.05. (e) Cilliated bronchosphere-forming assay. Bronchospheres were photographed at 0, 7 and 14 days. Scale 100 
μm. (e, far right) Bronchospheres contain keratin 5 (K5, red) positive basal cells and acetylated tubulin (ACT, green) 
positive ciliated cells and were counter stained with DAPI. Scales 100 μm and 20 μm (inset). (f) Bronchosphere 
cross-sectional area at the indicated time points. Results are the mean ± SD of n = 3 wells. * indicates p < 0.05 
relative to each of the other groups, by ANOVA.  
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6.2.2 Airway TSP1 and CD47 are minimally detectable in health and upregulated in 
epithelial cells following hypoxia. 
TSP1 protein is induced in lungs in response to bleomycin [219] and in airway neutrophils in 
human asthmatics [216]. Recent published reports have suggested that TSP1 can be a localizing 
signal which works in concert with BMP4 to drive differentiation toward an alveolar phenotype 
[139]. However, little is known about the homeostatic role of TSP1 in the proximal airway.  
Murine tracheas from healthy wild type mice did not display TSP1 on immunohistological 
staining of tissue sections (Figure 14a, on page 109). To more precisely explore this, we 
performed mass spectroscopy evaluation of tracheal samples. Platelet-derived human TSP1 
protein, as a positive control, was identified on mass spectroscopy. Pre-digested murine tracheas 
were protein separated via Western blot and gel bands at the predicted molecular weight for 
TSP1 analyzed via mass spectroscopy. Consistent with results above, TSP1 was not among 974 
proteins detected by mass spectroscopy in these preparations. Tissue injury through the 
disruption of normal perfusion induces hypoxia and ischemia, and these processes likely limit 
cellular restoration and healing of engineered tracheas [20]. As an in vitro mimic of injury we 
challenged HAECs to hypoxia (FiO2 1%, 2 and 12 hours). Both TSP1 and CD47 protein 
expression increased significantly in HAECs following hypoxia (Figure 14b). The finding of 
hypoxia-mediated induction of TSP1 and CD47 in HAECs is relevant as we reported CD47 is 
the cognate cell receptor for TSP1 [220]. 
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Figure 14.  Hypoxic challenge of human airway epithelial cells (HAECs)  (a) TSP1 and CD47 protein levels in 
HAECs exposed to hypoxia (FiO2 = 1%) for 2 and 12 hours. (b) Protein levels of multiple self-renewal transcription 
factors following 12-hour hypoxic challenge (FiO2 = 1%) of HAECs. Results are the mean ± SD of n=3 separate 
experiments. * indicates p < 0.05. 
 
 
 
6.2.3 Maladaptive induction of TSP1-CD47 signaling in HAEC limits self-renewal gene 
expression. 
We published that TSP1-CD47 signaling limited self-renewal gene expression in kidneys 
following ischemia reperfusion injury [103]. Consistent with these findings, the hypoxia-
mediated upregulation of TSP1 and CD47 in HAEC correlated with a significant decrease in 
mRNA expression of several self-renewal genes including cellular homolog of the v-myc avian 
myelocytomatosis viral oncogene homolog (c-Myc) and sex determining region Y-box 2 (Sox2) 
(Figure 14b). Treating cells with a CD47 blocking antibody (clone B6H12, 1.0 µg/ml) restored c-
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myc and Sox2 levels and increased octamer-binding transcription factor 4 (Oct4) levels beyond 
those found in normoxic control cells (Figure 14b). 
6.2.4 Airway cell seeding on decellularized and synthetic tracheal scaffolds is associated 
with TSP1 expression.  
To begin to investigate the role of TSP1-CD47 signaling in a tissue relevant setting we 
decellularized porcine tracheas and proximal airways as summarized in Figure 15a. Hematoxylin 
and eosin (H&E) staining demonstrated total cellular removal from the airway mucosal lining, 
although some cellular material was still present in cartilaginous rings (Figure 15b).  
Control experiments found no detectable soluble TSP1 protein in stock HAEC media and 
matrix-conditioned HAEC media on ELISA (Figure 15c).  However, immunoreactive TSP1 was 
histologically observed in intact porcine tracheas but was undetectable in decellularized porcine 
tracheal matrix (PTM) prior to cell seeding (Figure 15d). In contrast, immunoreactive TSP1 was 
detected in scaffolds (Figure 15d) 72 h following HAEC seeding. Interestingly, HAEC seeded 
onto both decellularized porcine trachea scaffolds and synthetic tracheal scaffolds as well as 
collagen coated cell culture wells all displayed TSP1 (Figure 15c) although absolute levels 
varied possible, in part, secondary to variation in cell adhesion and thus cell number.    
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Figure 15. Airway cell seeding on decellularized and synthetic tracheal scaffolds is associated with TSP1 
expression. (a) Serial washes under cyclic vacuum pressure effectively remove cellular material from porcine 
tracheas. (b) Hematoxylin and eosin stains of intact and decellularized tracheas. In both images, the lumen is at the 
upper right.  Scale bar 100 microns (main image) and 20 microns (inset). (c) From left to right: TSP1 content in 
stock media, in media taken from cells seeded on collagen, in PTM-conditioned media, and media taken from cells 
seeded on PTM, after 72 hours. (d) Left, immunohistochemistry: TSP1 content in intact porcine trachea, porcine 
tracheal matrix, and HAEC seeded scaffolds. Right, immunofluorescence for keratin 5 (K5, red) keratin 14 (K14, 
green) and both (yellow), with a DAPI counterstain.  (e) Quantification of dual-positive cells attached to PTM after 
seeding.   
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6.2.5 Blockade of TSP1-CD47 signaling does not alter HAEC adhesion to porcine tracheal 
matrix. 
Lack of CD47 has been found to decrease adhesion in some cells [221]. Having found that TSP1 
is expressed following airway cell seeding of decellularized airway scaffolds and that in cultured 
HAEC treatment with a CD47 blocking antibody increases self-renewal gene expression, we 
hypothesized that CD47 blockade might also alter HAEC adhesion to porcine airway scaffolds. 
HAEC (1x105/scaffold) were seeded onto porcine decellularized airway scaffolds cut to fit 
within wells of 24-well plates. Cells were then treated with a CD47 blocking antibody (1.0 
ug/ml). Histological stains showed no difference in nuclear counts in scaffolds treated with the 
CD47-blocking antibody versus the untreated controls (Figure 15e).   
6.2.6 Absence of CD47 is associated with increased expression of self-renewal genes in the 
trachea and proximal airway. 
New in vitro and ex vivo data suggests that TSP1-CD47 signaling limits airway healing. 
However, it was not clear if this signaling pathway was also suppressing airway restoration in 
vivo. We have previously reported that CD47 null mice display constitutive upregulation of the 
key self-renewal OSKM genes in tissues and isolated cells [103, 187].  Extending these studies, 
we characterized the expression profile of relevant genes in freshly harvested tracheas and 
proximal airways from male age-matched wild type and CD47 null mice. As expected, CD47 
protein was not detected in tracheas from CD47 null mice (Figure 16a on page 114), although 
low levels of CD47 transcript were found (Figure 16b). In keeping with previously published 
reports [187], key genes associated with cellular self-renewal including Kl4 and Sox2 were 
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upregulated in airway tissue from CD47 null mice (Figure 16c). Coincident with this, tracheal 
and airway samples from CD47 null mice showed greater levels of the basal progenitor cell 
marker keratin 5 relative to samples from wild type controls (Figure 16d).  Finally, tracheas and 
proximal airways from CD47 null mice displayed  a greater number of cells expressing Ki67, a 
protein required for cell proliferation and increased during activation of the cell cycle [222], 
along the tracheal epithelium when compared to similar airway samples from wild type mice 
(Figure 16e).   
6.2.7 CD47 null tracheas display enhanced angiogenic activity ex vivo 
In the airway, it is thought that the rapid revascularization of a decellularized tracheal transplant, 
a process that likely involves both stromal and vascular cells [103], can promote re-
epithelialization and prevent transplant loss [20].  Employing a model of tissue explantation we 
tested the angiogenic potential of tracheas and proximal airways ex vivo. The tissue explant 
outgrowth assay has been previously described in the literature and is recognized as a measure of 
angiogenic potential [184]. Explanted fresh tracheal segments from age-matched male wild type 
and CD47 null mice were embedded in type I collagen gels and cellular migration was 
quantified. After five days, cellular migration into the collagen gel was greater in CD47 null 
tracheal explants relative to wild type controls. (Figure 16g, h)  These results suggest increased 
wound healing capacity in CD47 null tracheas relative to those from wild-type mice.  
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Figure 16. Self-renewal, cell cycle activation and angiogenic responses are increased in CD47 null tracheas. 
(a) Western blot for CD47 protein. (b, c, d) Transcript levels of (b) Cd47 and TSP1 gene Thbs1, (c) airway epithelial 
markers and (d) self-renewal markers (n = 5-7 tracheas, * indicates p < 0.05, error bars denote SD). (e, f) 
Quantification of Ki67+ nuclei along the airway epithelium at baseline (n = 3 animals, 9 rings counted per animal.  * 
indicates p < 0.05, error bars denote SD, scale bar 50 μm.). (g) Explant outgrowth, is an ex vivo model of angiogenic 
capacity.  (h) Explant outgrowth, quantified.  Each symbol represents the mean distance traveled by the furthest 20 
objects identified in each image captured of each ring. Each symbol represents one of n = 3 animals, error bars 
denote 1 SD, * indicates p < 0.05. Scale bar 200 μm.    
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6.2.8 Absence of CD47 provides for enhanced healing from chemical airway injury 
Constitutive expression of increased proliferative and self-renewal genes in CD47 null airways 
might not correlate with improved healing after acute injury in vivo. To test this we employed 
intraperitoneal naphthalene, a commonly-used agent that provides for a reproducible degree of 
airway epithelial injury [22, 26-28]. Club cells within the airway epithelium convert naphthalene 
into a toxic metabolite which destroys these cells and adjacent non-club cells.  During the first 
week after naphthalene injury, keratin-5 (K5) expressing basal cells upregulate keratin-14 (K14), 
proliferate, and resurface the luminal surface of the trachea (Figure 17a) subsequently 
differentiating into the several cell types of the airway epithelium over the next several weeks.  
Given our in vitro results, we hypothesized that the early stages of this process (proliferation and 
resurfacing) would be accelerated in the trachea and proximal airways of CD47 null mice.   
Age-matched male CD47 null and wild type mice received naphthalene (275 mg/kg, i.p.) 
and at the indicated time points tissue samples were acquired for analysis via immunohistology 
and Western blot. Immunofluorescent staining of tracheas collected four days after injury 
demonstrated patches of keratin-5/keratin-14 dual staining cells.  Four days after injury, a greater 
percentage of the luminal surface was covered with dual-staining cells in airways from CD47 
null mice when compared to WT mice (Figure 17b). Approximately equal numbers of Ki67+ 
cells were observed at both time points (Figure 17c).  
To further examine the observed differences in healing at four days, Western blots on 
were performed on bronchiolar tissue.  Wild type mice upregulated CD47 and TSP1 in response 
to injury. Airway samples from both WT and CD47 null mice demonstrated lower levels of 
CC10, a marker of club cells, however CD47 null samples nonetheless displayed greater levels 
than their WT counterparts (Figure 17d). We also examined the expression of OSKM markers of 
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self-renewal, in addition to the ΔN isoform of p63. In particular, Sox2 [15, 223], c-Myc [224], 
and ΔNp63 [225, 226] are associated with airway basal cell self-renewal and wound repair in 
vivo. After global chemical airway injury, CD47 null tissues showed greater levels of the 
transcription factor c-Myc and of ΔNp63 compared to wild-type mice (Figure 17e).   
6.2.9 Absence of CD47 is associated with accelerated resurfacing of decellularized 
orthotopic tracheal transplants. 
Data in mice indicates that the maladaptive TSP1-CD47 signal limits airway restoration 
following chemical injury. However, this is not exactly comparable to the complex healing of 
transplanted decellularized tracheal scaffolds. To integrate the role of the TSP1-CD47 axis in 
tracheal transplantation we conducted full orthotopic tracheal transplantation of decellularized 
tracheas obtained from wild type donor mice into both wild type and CD47 null recipient 
animals, as previously described [1]. After transplantation, keratin-5 expressing basal cells 
proliferate rapidly, upregulate keratin-14, and migrate into the graft to resurface the 
decellularized trachea in a manner reminiscent of wound healing after naphthalene injury [22, 
26-28] (Figure 18a, b). Our previous study [1] has shown that the luminal surface of the 
decellularized tracheal transplant is completely re-surfaced with keratin-5/keratin-14 dual-
expressing basal cells by post-transplant day seven.  Since new data demonstrated a difference in 
self-renewal gene expression between tracheas and airways from wild type and CD47 null mice 
four days after naphthalene injury, we hypothesized that an examination of K5+/K14+ 
expression after four days would demonstrate more rapid resurfacing of decellularized grafts 
transplanted into CD47 null mice.  
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Epithelial migration was measured from the far end of the native tracheal ring adjacent to 
the anastomosis to the leading edge of basal cell migration, as identified by keratin-5/keratin-14 
dual staining (Figure 18b). As predicted, wild type decellularized tracheal transplants into 
orthotopic tracheal defects in CD47 null mice showed more rapid basal cell resurfacing than 
similar decellularized tracheal transplants into wild-type recipients (Figure 18c).   
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Figure 17.   CD47 null mice show greater expression of self-renewal markers 4 days after naphthalene airway 
injury.  (a) Male WT and CD47 null mice were treated with 275 mg/kg naphthalene in corn oil, i.p., and sacrificed 
after 4 or 7 days.  A patchy distribution of squamoid epithelial cells was visible after 4 days. (b) Fraction of surface 
coverage at 4 and 7 days, calculated as (length of lumen covered with dual positive cells) / (total length of lumen 
measured).  (c) Ki67+ cells along the airway lumen after naphthalene injury.  (d) CD47 and TSP1 expression in WT 
and CD47 null mice after four days. (e) Transcription factor expression in WT and CD47 null mice after 4 days. (n = 
3-4 tracheas, * indicates p < 0.05 by t-test, error bars denote SD).  
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Figure 18. Absence of CD47 accelerates resurfacing of decellularized orthotopic tracheal transplants.  (a) 
Hematoxylin and eosin staining of a representative slide at the site of anastomoses. (b) Immunolabeling 
demonstrates a clear migratory front. Dotted line indicates measured distance.   In image, * = decellularized graft 
ring. Scale 100 μm and applies to (a, b). (c) Quantification of migration from n = 3 mice in each group.  (* indicates 
p < 0.05, bars denote SD.) 
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6.3 DISCUSSION 
Clinical human bioengineered tracheal transplantation has been hampered by significant 
morbidity and mortality and a lack of evidence confirming transplant integration and healing. 
However, the molecular cues responsible for these disappointing outcomes remain unknown. In 
contrast, we herein provide data that maladaptive TSP1-CD47 is a major impediment to tracheal 
epithelial and tracheal transplant healing. The findings of this study are novel and include (1) that 
TSP1 is induced in isolated airway epithelial cells on seeding onto decellularized scaffolds, (2) 
that hypoxia, as a mimic of the tracheal transplantation injury, is a potent stimulator of TSP1 
expression in human airway epithelial cells; (3) that in cell culture systems TSP1 can impede 
tracheal epithelial cell proliferation and this can be reversed by interference with TSP1-CD47 
interaction; (4) that genetic absence of TSP1-CD47 signaling  is associated with an enhanced 
restorative profile in isolated airway epithelial cells, increased angiogenic sprouting of airways in 
response to hypoxia and (5) increased tracheal/proximal airway healing after chemical ablation 
and resurfacing of decellularized tracheal transplants. The translational significance of these 
findings is emphasized by the fact that humanized CD47 antibodies have been generated [227] 
and recently entered clinical trials [228].  
Regeneration is a function of cell reprograming from differentiated to de-differentiated 
followed by migration, proliferation and finally differentiation. TSP1 has been previously shown 
to inhibit the migration of endothelial cells [148] while promoting migration of certain other cell 
populations [229]. In our study, the presence of TSP1 in media did not alter the rate at which 
human airway epithelial cells resurfaced a wound. In contrast, the CD47 blocking antibody 
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B6H12 promoted wound closure in both the presence and absence of TSP1. At the same time 
TSP1 limited tracheal epithelial cell proliferation via CD47. Together, these data suggest that in 
vitro TSP1 preferentially targets the epithelial cell cycle and thus proliferation rather than 
migration. Whole tissue data supports this as the lack of TSP1-CD47 signaling in tracheas from 
null mice was associated with increased expression of the essential proliferation gene Ki67. We 
recently reported that hypoxia via HIF-2α induced upregulation of TSP1 in pulmonary arterial 
endothelial cells [159]. We now find that hypoxia also potently induces TSP1 in pulmonary 
epithelial cells. However, in hypoxic pulmonary endothelial cells TSP1 promoted increased 
migration [159]. It is possible that under hypoxic conditions TSP1 would alter tracheal epithelial 
cells migration to enhance in vitro wound closure but this was not tested.  
Regardless, these new and published studies suggest that under the ischemic and hypoxic 
stress of bioengineered tracheal transplantation induction of TSP1 would target multiple cells 
types including endothelial and epithelial cells to limit cellular reprogramming, restoration and 
healing. The finding of increased expression of the reprograming/self-renewal cassette OSKM in 
CD47 null tracheal epithelial cells indicates that the TSP1-CD47 axis is a constitutive and 
proximate inhibitor of this process in the airway. CD47 null mice enjoyed healing advantages 
after airway chemical ablation as well as after orthotopic decellularized tracheal transplantation. 
These new findings are consistent with previous reports indicated improved tissue healing in the 
absence of CD47 [106, 107]. In some of these situations more rapid healing was associated with 
increased tissue blood flow in the CD47 null animals. While a tissue perfusion advantage may 
have promoted enhanced healing in CD47 null mice after naphthalene compared to wild type, 
this was less likely to have been a factor in the orthotopic decellularized tracheal transplant 
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model. Thus, in the proximal airway TSP1-CD47 signaling appears to limit healing in both blood 
flow-dependent and -independent mechanisms.  
Limitations of this work are several. First, the murine model of orthotopic 
transplantation, while providing confirmation of the role of TSP-1CD47 signaling plays in 
limiting the healing of decellularized tracheal transplants, does not fully recapitulate the complex 
environment of human tracheal transplantation. Especially obvious is the ability of decellularized 
transplants to survive in mice in the absence of soft tissue flaps as a source of angiogenesis and 
immune cells. Although angiogenic activity was greater in CD47 null tracheal explants 
compared to wild type, the implications of this were not assessed in our analysis of 
decellularized tracheal transplants. Another limitation is that it is not clear what role, if any, the 
TSP1-CD47 axis plays in regulating chondrocyte restoration. TSP1 is expressed in mature 
chondrocytes [230, 231] whereas CD47 is induced during chondrocyte differentiation [232]. 
Conversely, chondrocyte dedifferentiation is maintained by Klf4 [233], and as we have reported 
TSP1-CD47 signaling represses Klf4 [187]. Together these results suggest that hypothesis that 
TSP1-CD47 signaling also targets chondrocytes to limit cartilage restoration. It remains to be 
seen if chondrocyte repopulation of decellularized tracheal matrix is regulated by TSP1-CD47. 
Finally, the ability of a CD47 blocking antibody to improve the healing of decellularized tracheal 
transplant in wild type animals requires testing.  
6.4 CONCLUSIONS 
We hypothesized that TSP1-CD47 signaling is induced in airway epithelial and endothelial cells 
to limit restoration of decellularized tracheal transplants. The experiments described herein 
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demonstrate that TSP1-CD47 signaling is upregulated in hypoxic tracheal epithelial cells, in 
chemically injured airways, in epithelial cells seeded on decellularized grafts, and in engineered 
tracheal transplants. CD47 null mice have higher tracheal levels of self-renewal factors at 
baseline and after injury. In keeping with this observation, they show more rapid resurfacing 
after chemical injury and orthotopic decellularized tracheal transplantation. These findings 
suggest that modulation of the TSP1-CD47 signaling pathway could be beneficial in 
bioengineered transplants.  Future experiments will examine the role of TSP1 and CD47 
signaling in synthetic tracheal grafts, and will explore the use of CD47 blocking antibodies as a 
therapeutic agent to promote cell survival within tissue engineered grafts.  
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APPENDIX A 
CYTOANALYSIS: A PROGRAM TO ANALYZE CYTOSPIN SLIDES 
This script was developed in order to perform automated image analysis on cytospin slides, and sort cells into (“high”) and (“low”) 
expression categories along one or two axes (in a manner similar to flow sorting.)  The program was written by the author.  Usage is 
as follows.  
runcytoanalysis(folder, filters, markers, universalmarker, minsharedpixelfraction, intensitythreshold, 
minArea, maxArea, outputfile) 
 
folder = the folder containing all the images to be analyzed; filters and markers = arrays of (1) file type filters and the markers they 
correspond to.  For instance, the first row in each of those arrays might be “*dapi*.tif” and “DAPI”; the program would associate any 
file matching the filter given with the DAPI marker.  universalmarker  is the index of the marker which should stain all cells (e.g., 
DAPI).  Intesnitythreshold is the pixel value threshold corresponding to the boundary between “High” and “Low” expression of a 
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given marker. minsharedpixelfraction tells how much two objects must overlap with the universal marker before they are considered 
to be the same object – e.g., if minsharedpixelfraction  = 0.6, then an object in the red channel must share (60%) of its pixels with an 
object in the universal channel in order to associate them in program memory.  minArea and maxArea allow the user to filter out 
objects which are too small or two large.  outputfile is a data file which receives the summary data.   
 
A.1 RUNCYTOANALYSIS 
function [allvalues] = runcytoanalysis(folder, filters, markers, universalmarker, minsharedpixelfraction, 
intensitythreshold, minArea, maxArea, outputfile) 
  
% minsharedpixelfraction is the fraction of pixels an object must share with a 
% cell stained with the universal marker in order to be considered the same 
% cell.  The minimum area for this is a fraction of the smaller object' 
% area.   
  
xlswrite(outputfile, {' ', 'Mean (I)' , 'Stdev (I)', 'n (I)', 'Intensity Threshold', 'Mean (area)', 'Stdev 
(area)'}, 'Summary', 'A1'); 
summaryrow = 2; 
  
% Build file list for the universal marker, and generate a list of pixels 
% for each cell stained by the universal marker. 
if ~strcmp(universalmarker, '') 
    m = find(ismember(markers, {universalmarker})); 
    [status, text] = system(char(strcat('dir "',folder, filters(m),'" /b'))); 
    umfilelist = strsplit(text, char(10)); 
    for f = 1:length(umfilelist) - 1 
        gray = imread(char(fullfile(folder,umfilelist(f)))); 
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        mask = im2bw(gray, graythresh(gray)); 
         
        % Build pixel lists which can be accessed with  
        %       umimstats{[file number]}([cell number]).PxlIdxList 
        umimstats{f} = regionprops(mask, gray, {'Area', 'MeanIntensity', 'PixelIdxList'}); 
        [umimstats{f}(:).IValues] = deal(zeros(length(markers), 1)); 
  
        % Remove objects which are too small to be cells 
        j = 1; 
        while j < length(umimstats{f}) 
            if (umimstats{f}(j).Area < minArea(m)) || (umimstats{f}(j).Area > maxArea(m)) 
                umimstats{f}(j) = []; 
            else 
                umimstats{f}(j).IValues(m) = umimstats{f}(j).MeanIntensity; 
                j = j + 1; 
            end 
        end  
        % pp = umimstats{f}(1).PixelIdxList         
  
    end 
end  
  
for m = 1:length(markers) 
    [status, text] = system(char(strcat('dir "',folder, filters(m),'" /b'))); 
    filelist = strsplit(text, char(10)); 
  
    area = []; 
    centroid = []; 
    centroidx = []; 
    centroidy = []; 
    meanI = []; 
    minI = []; 
    maxI = []; 
    threshold = []; 
     
     
     
    for i = 1:length(filelist) - 1 
         
        gray = imread(char(fullfile(folder,filelist(i)))); 
        mask = im2bw(gray, graythresh(gray)); 
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        % Keep in mind that the output of imstats will not necessarily be in the order given below. 
        imstats = regionprops(mask, gray, {'Area', 'Centroid', 'PixelIdxList', 'MeanIntensity', 
'MinIntensity', 'MaxIntensity'}); 
        % umimstats{f}(1).area 
        j = 1; 
         
        while j < (length(imstats)) 
            if (imstats(j).Area < minArea(m)) || (imstats(j).Area > maxArea(m)) 
                imstats(j) = []; 
            else  
                % See how many of my pixels correspond to a given item in the unversal marker list                 
                if ~strcmp(universalmarker, '') && ~strcmp(universalmarker, markers(m)) 
                    for k = 1:length(umimstats{i}) 
                        overlap = length(intersect(imstats(j).PixelIdxList, umimstats{i}(k).PixelIdxList)); 
                        if overlap > 0 
                             
                            if imstats(j).Area < umimstats{i}(k).Area 
                                smallerarea = length(imstats(j).PixelIdxList); 
                            else 
                                smallerarea = length(umimstats{i}(k).PixelIdxList); 
                            end 
                            overlapratio = overlap/smallerarea; 
                            if minsharedpixelfraction <= overlapratio 
                                umimstats{i}(k).IValues(m) = imstats(j).MeanIntensity; 
  
                            end  
                            break;  % Leave the loop, since we've found your match 
                        end 
                    end 
                end  
  
                j = j + 1;  
  
             end  
        end  
         
        imstatsarray = struct2cell(imstats); 
        area = [area cell2mat(imstatsarray(1, :, :))]; 
        centroid = cell2mat(imstatsarray(2, :, :)); 
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        for c = 1:length(centroid)/2 
            centroidx = [centroidx centroid(c*2-1)] ; 
            centroidy = [centroidy centroid(c*2)] ; 
        end  
         
        meanI = [meanI cell2mat(imstatsarray(4, :, :))]; 
        minI = [minI cell2mat(imstatsarray(5, :, :))]; 
        maxI = [maxI cell2mat(imstatsarray(6, :, :))]; 
         
    end 
     
  
     
     
    % Determine whether each cell's intensity value exceeded the threshold 
    threshold = (meanI >= intensitythreshold(m)); 
     
    % Sort intensities and areas depending on whether or not cells 
    % exceeded the threshold. 
    posI = []; 
    posA = []; 
    negI = []; 
    negA = []; 
     
    for j = 1:length(threshold) 
        if threshold(j) == 1 
            posI = [posI meanI(j)]; 
            posA = [posA area(j)]; 
        else 
            negI = [negI meanI(j)]; 
            negA = [negA area(j)];  
        end 
    end 
     
  
    % Write all my data to the sheet in the output file 
    header = {'Area', 'CentroidX', 'CentroidY', 'MeanI', 'MinI', ' MaxI', 'Exceeds Threshold'}; 
    xlsarray = transpose([area; centroidx; centroidy; meanI; double(minI); double(maxI); 
double(threshold)]); 
    xlswrite(outputfile, header, char(markers(m))); 
    xlswrite(outputfile, xlsarray, char(markers(m)), 'A2'); 
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    % Write to summary data to summary sheet in output file 
    xlswrite(outputfile, [markers(m), mean(meanI), std(meanI), length(meanI), intensitythreshold(m), 
mean(area), std(area)], 'Summary', ['A' int2str(summaryrow)]); 
    xlswrite(outputfile, [strcat(markers(m),', I>threshold'), mean(posI), std(posI), length(posI), ' ', 
mean(posA), std(posA)], 'Summary', ['A' int2str(summaryrow+1)]); 
    xlswrite(outputfile, [strcat(markers(m),', I<threshold'), mean(negI), std(negI), length(negI), ' ', 
mean(negA), std(negA)], 'Summary', ['A' int2str(summaryrow+2)]); 
    summaryrow = summaryrow + 3; 
         
end 
allvalues = []; 
for i = 1:(length(filelist) - 1) 
    for k = 1:(length(umimstats{i})) 
        allvalues = [allvalues ; transpose(umimstats{i}(k).IValues)]; 
    end 
end 
  
xlswrite(outputfile, markers, 'All Cells', 'A1'); 
xlswrite(outputfile, allvalues, 'All Cells', 'A2'); 
  
%  
return 
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APPENDIX B 
EXPLANTDATA: A SCRIPT TO QUANTIFY EXPLANT ASSAYS 
This script was written by me, with the exception of the function p_poly_dist which calculates the distance between a point and a 
polygon.   Usage is as follows: 
explantdata(path, ext, fileOut1, pixelspermicron, maxN) 
path = the folder containing all ‘.dat’ files (without a backslash at the end) ; ext = the file extension (‘*.dat’); fileOut = the 
output spreadsheet; pixelspermicron = a conversion factor which depends on the magnification; and maxN = the maximum number 
of cells to use when calculating distances.  The program will calculate the mean distance traveled by the furthest maxN cells in the 
image.  
Example: 
explantdata('K:\Data\20130811', '*.dat', '20130811.xls', 1.0, 20) 
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B.1 FILE: EXPLANTDATA.M 
function explantdata(path, ext, fileOut1, pixelspermicron, maxN) 
  
files = dir ([path '\*' ext]); 
s = size(files); 
A = []; 
cells = []; 
polygon = []; 
mymed = 0; 
mymean = 0; 
mystdev = 0; 
myN = 0; 
myArea = 0; 
myName = ''; 
fileOut = [path '\' fileOut1]; 
xlswrite(fileOut, [cellstr('File') cellstr('Mean dist') cellstr('StDev') cellstr('N') cellstr('Median 
dist') cellstr('PolyArea')], 'Summary', 'A1:F1'); 
for f = [1:s(1)] 
    A = []; 
    cells = []; 
    polygon = []; 
    mymed = 0; 
    mymean = 0; 
    mystdev = 0; 
    myN = 0; 
    myArea = 0; 
    myName = files(f).name; 
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    xlswrite(fileOut, [cellstr('x') cellstr('y') cellstr('dist')], myName, 'A1:C1'); 
    xlswrite(fileOut, [cellstr('Mean dist'); cellstr('StDev'); cellstr('N'); cellstr('Median dist'); 
cellstr('PolyArea')], myName, 'E1:E5'); 
    xlswrite(fileOut, [cellstr('poly x') cellstr('poly y')], myName, 'H1:I1'); 
     
    A = importdata([path '\' myName]); 
    disp (['Analyzing ' myName '...']); 
     
    [cells, polygon] = analyzeexplantdata(A.data, 1, 2, pixelspermicron); 
     
    cells = sortrows(cells, 3); 
     
    if length(polygon(:, 1)) < 3 
        disp(['Warning: ' files(f).name ' has insufficient polygon points defined.']) 
         
    else 
        myArea = polyarea(polygon(:, 1), polygon(:, 2)); 
        xlswrite(fileOut, myArea, myName, 'F5'); 
        xlswrite(fileOut, [polygon], myName, ['H2:I' num2str(length(polygon(:, 1))+1)]); 
    end 
     
    if size(cells) == [0, 0] 
        disp(['Warning: ' files(f).name ' has insufficient cells defined.']) 
    else 
         
        myN = length(cells(:, 3));  
         
        if maxN ~= -1  
            if myN > maxN 
                cells = cells(myN-maxN + 1:myN, :); 
                myN = length(cells(:, 3));  
            end 
        end 
         
        mymed = median(cells(:, 3)); 
        mymean = mean(cells(:, 3)); 
        mystdev = std(cells(:, 3)); 
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        xlswrite(fileOut, [cells], myName, ['A2:C' num2str(myN+1)]); 
        xlswrite(fileOut, [mymean; mystdev; myN; mymed], myName, 'F1:F4'); 
  
    end 
    xlswrite(fileOut, [cellstr(myName) num2str(mymean) num2str(mystdev) num2str(myN) num2str(mymed) 
num2str(myArea)], 'Summary', ['A' num2str(f+1) ':F' num2str(f+1)]);     
     
end 
  
disp('Done.'); 
  
end 
  
function [cells, polygon] = analyzeexplantdata(datamatrixfromfile, celltypeID, polygontypeID, 
pixelspermicron) 
s = size(datamatrixfromfile); 
polygon = []; 
cells = []; 
for r = [1:s(1)] 
    if datamatrixfromfile(r, 1) == polygontypeID 
        newrow = [datamatrixfromfile(r, 3) datamatrixfromfile(r, 4)]; 
        polygon = [polygon; newrow]; 
    elseif datamatrixfromfile(r, 1) == celltypeID 
        newrow = [datamatrixfromfile(r, 3) datamatrixfromfile(r, 4) -1]; 
        cells = [cells; newrow]; 
    end 
end 
  
s = size(cells); 
for r = [1:s(1)] 
    cells(r, 3) = p_poly_dist(cells(r, 1), cells(r, 2), polygon(:, 1), polygon(:, 2)); 
end 
cells = cells / pixelspermicron; 
polygon = polygon / pixelspermicron; 
  
end 
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%******************************************************************************* 
% function: p_poly_dist 
% Description:  distance from point to polygon whose vertices are specified by the 
%              vectors xv and yv 
% Input:   
%    x - point's x coordinate 
%    y - point's y coordinate 
%    xv - vector of polygon vertices x coordinates 
%    yv - vector of polygon vertices x coordinates 
% Output:  
%    d - distance from point to polygon (defined as a minimal distance from  
%        point to any of polygon's ribs, positive if the point is outside the 
%        polygon and negative otherwise) 
%    x_poly: x coordinate of the point in the polygon closest to x,y 
%    y_poly: y coordinate of the point in the polygon closest to x,y 
% 
% Routines: p_poly_dist.m 
% Revision history: 
%    03/31/2008 - return the point of the polygon closest to x,y 
%               - added the test for the case where a polygon rib is  
%                 either horizontal or vertical. From Eric Schmitz. 
%               - Changes by Alejandro Weinstein 
%    7/9/2006  - case when all projections are outside of polygon ribs 
%    23/5/2004 - created by Michael Yoshpe  
% Remarks: 
%******************************************************************************* 
function [d,x_poly,y_poly] = p_poly_dist(x, y, xv, yv)  
  
% If (xv,yv) is not closed, close it. 
xv = xv(:); 
yv = yv(:); 
Nv = length(xv); 
if ((xv(1) ~= xv(Nv)) || (yv(1) ~= yv(Nv))) 
    xv = [xv ; xv(1)]; 
    yv = [yv ; yv(1)]; 
%     Nv = Nv + 1; 
end 
  
% linear parameters of segments that connect the vertices 
% Ax + By + C = 0 
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A = -diff(yv); 
B =  diff(xv); 
C = yv(2:end).*xv(1:end-1) - xv(2:end).*yv(1:end-1); 
  
% find the projection of point (x,y) on each rib 
AB = 1./(A.^2 + B.^2); 
vv = (A*x+B*y+C); 
xp = x - (A.*AB).*vv; 
yp = y - (B.*AB).*vv; 
  
% Test for the case where a polygon rib is  
% either horizontal or vertical. From Eric Schmitz 
id = find(diff(xv)==0); 
xp(id)=xv(id); 
clear id 
id = find(diff(yv)==0); 
yp(id)=yv(id); 
  
% find all cases where projected point is inside the segment 
idx_x = (((xp>=xv(1:end-1)) & (xp<=xv(2:end))) | ((xp>=xv(2:end)) & (xp<=xv(1:end-1)))); 
idx_y = (((yp>=yv(1:end-1)) & (yp<=yv(2:end))) | ((yp>=yv(2:end)) & (yp<=yv(1:end-1)))); 
idx = idx_x & idx_y; 
  
% distance from point (x,y) to the vertices 
dv = sqrt((xv(1:end-1)-x).^2 + (yv(1:end-1)-y).^2); 
  
if(~any(idx)) % all projections are outside of polygon ribs 
   [d,I] = min(dv); 
   x_poly = xv(I); 
   y_poly = yv(I); 
else 
   % distance from point (x,y) to the projection on ribs 
   dp = sqrt((xp(idx)-x).^2 + (yp(idx)-y).^2); 
   [min_dv,I1] = min(dv); 
   [min_dp,I2] = min(dp); 
   [d,I] = min([min_dv min_dp]); 
   if I==1, %the closest point is one of the vertices 
       x_poly = xv(I1); 
       y_poly = yv(I1); 
   elseif I==2, %the closest point is one of the projections 
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       idxs = find(idx); 
       x_poly = xp(idxs(I2)); 
       y_poly = yp(idxs(I2)); 
   end 
end 
  
if(inpolygon(x, y, xv, yv))  
   d = -d; 
end 
 
end  
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